Notis Global (NGBL) 10-Q/A 16 Mar 15 2014 Q3 Quarterly report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 12, 2014
Document And Entity Information [Abstract]
Document Type	10-Q/A
Amendment Flag	TRUE
Amendment Description	This Amendment No. 1 to Medbox, Inc.’s Form 10-Q for the three and nine months ended September 30, 2014, initially filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 11, 2014 (the “Original Filing”), includes restated condensed consolidated financial statements for the three and nine months ended September 30, 2014 and 2013 (the “Restated Financials”) and a revised Management’s Discussion and Analysis of Financial Condition and Results of Operations, which has been amended to provide disclosure regarding the effect of the Restated Financials. The unaudited condensed consolidated financial statements of the Company contained in the Original Filing have been restated to correct errors relating to (i) the timing of recognition of certain revenues for certain customer contracts prior to the period in which they were earned, (ii) recognition of investments from related parties as capital contributions, and (iii) improper capitalization of inventory costs. See Note 15 to the Company’s condensed consolidated financial statements included in “Item 1. Financial Statements” of this report and the information set forth in “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” for additional information. The Company also has restated its unaudited condensed consolidated financial statements as of and for the quarterly periods ended March 30 and June 30, 2014 and the audited condensed consolidated financial statements for the years ended December 31, 2013 and December 31, 2012 set forth in its General Form of Registration of Securities on Form 10 in connection herewith. The Company has amended and restated in its entirety each item of the Original Filing that required a change to reflect this restatement and to include certain additional information. These items include Item 1 and Item 2 of Part I and Item 6 of Part II of this report. No other information included in the Original Filing is amended hereby. Except as stated above, this Amendment speaks only as of November 11, 2014 (the “Original Filing Date”), and this filing has not been updated to reflect any events occurring after such date or to modify or update disclosures affected by other subsequent events. In particular, forward-looking statements included in this Amendment represent management’s views as of the Original Filing Date. Such forward-looking statements should not be assumed to be accurate as of any future date. This Amendment should be read in conjunction with the Company’s other filings made with the SEC subsequent to the Original Filing Date, together with any amendments to those filings. As previously disclosed in the Company’s Current Reports on Form 8-K filed on December 30, 2014 and March 9, 2015, respectively, the Company’s unaudited condensed consolidated financial statements previously included in the Original Filing, the Company’s audited condensed consolidated financial statements for the years ended December 31, 2012 and 2013 reported in the Company’s General Form of Registration of Securities on Form 10 and the unaudited condensed consolidated financial statements as of and for the quarterly periods ended March 31, and June 30, 2014 and 2013 should not be relied upon until restatements thereof have been filed with the SEC. Pursuant to Rule 12b-15 under the Securities and Exchange Act of 1934, as amended, this Form 10-Q/A includes new certifications by our principal executive officer and principal financial officer under Sections 302 and 906 of the Sarbanes-Oxley Act of 2002.
Document Period End Date	30-Sep-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3
Trading Symbol	MDBX
Entity Registrant Name	Medbox, Inc.
Entity Central Index Key	1547996
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		30,442,517

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 30, 2013	Sep. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$1,350,442	$168,003		$100,301	$1,026,902
Marketable securities	208,025	184,800	184,800
Accounts receivable	32,312	339,735
Note receivable	75,000	115,000
Inventory	522,198	632,986
Prepaid expenses and other current assets	1,012,195	89,241
Total current assets	3,200,172	1,529,765
Property and equipment, net of accumulated depreciation of $42,779 and $21,123, respectively	151,984	140,658
Assets held for resale	399,594	0
Investments, at cost	0	1,200,000
Intangible assets, net of accumulated amortization of $70,459 and $32,750 respectively	800,904	682,429
Note receivable	155,000	0
Goodwill	1,100,037	1,090,037
Deposits and other assets	72,726	98,726
Total assets	5,880,417	4,741,615
Current liabilities:
Accounts payable and accrued expenses	1,321,998	448,314
Deferred revenue	1,073,932	683,621
Notes payable	299,605	75,000
Related party notes payable	491,674	111,794
Convertible notes payable	1,939,801	0
Derivative liability	1,228,108	0
Customer deposits	1,584,808	785,861
Total current liabilities	7,939,926	2,104,590
Stockholders' Equity
Preferred stock, $0.001 par value: 10,000,000 authorized; 3,000,000 and 3,000,000 issued and outstanding as of September 30, 2014 and December 31, 2013, respectively	3,000	3,000
Common stock, $0.001 par value: 100,000,000 authorized, 30,105,331 and 29,525,750 issued and outstanding as of September 30, 2014 and December 31, 2013, respectively	30,105	29,526
Additional paid-in capital	11,615,278	8,156,358
Common stock subscribed	0	-15,000
Treasury stock	-1,209,600	0
Accumulated deficit	-12,339,785	-5,536,859
Accumulated other comprehensive loss	-158,507	0
Total stockholders' equity	-2,059,509	2,637,025			-153,629
Total liabilities and stockholders' equity	$5,880,417	$4,741,615

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Property and equipment, accumulated depreciation (in Dollars)	$42,779	$21,123
Intangible assets, accumulated amortization (in Dollars)	$70,459	$32,750
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, authorized	100,000,000	100,000,000
Common stock, issued	30,105,331	29,525,750
Common stock, outstanding	30,105,331	29,525,750
Series A Preferred Stock [Member]
Preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	3,000,000	3,000,000
Preferred stock, outstanding	3,000,000	3,000,000

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Income Statement [Abstract]
Revenues	$173,076	$1,314,178	$534,082	$1,844,376
Revenues, related parties	0	0	50,110	0
Less: allowances and refunds	0	0	-60,000	0
Net revenue	173,076	1,314,178	524,192	1,844,376
Cost of revenues	1,813,562	1,807,030	3,492,105	2,258,127
Gross margin	-1,640,486	-492,852	-2,967,913	-413,751
Operating expenses
Selling and marketing	319,204	91,136	749,212	506,393
Research and development	61,623	28,233	136,656	46,733
General and administrative	952,663	522,372	2,151,742	1,876,505
Stock based compensation	1,031,640	0	1,031,640	0
Total operating expenses	2,365,130	641,741	4,069,250	2,429,631
Loss from operations	-4,005,616	-1,134,593	-7,037,163	-2,843,382
Other income (expense)
Interest income (expense), net	-339,231	4,311	-314,078	-1,884
Change in fair value of derivative liabilities	548,315	0	548,315	0
Total other income (expense)	209,084	4,311	234,237	-1,884
Loss before provision for income taxes	-3,796,532	-1,130,282	-6,802,926	-2,845,266
Provision for income taxes	0	-119,280	0	-29,220
Net loss	-3,796,532	-1,011,002	-6,802,926	-2,816,046	-3,791,440
Earnings per share attributable to common stockholders
Basic (in Dollars per share)	($0.13)	($0.03)	($0.22)	($0.10)
Diluted (in Dollars per share)	($0.13)	($0.03)	($0.22)	($0.10)
Weighted average shares outstanding
Basic (in Shares)	30,371,299	29,298,284	30,472,447	28,658,556
Diluted (in Shares)	30,371,299	29,298,284	30,472,447	28,658,556
Other Comprehensive loss
Net loss	-3,796,532	-1,011,002	-6,802,926	-2,816,046	-3,791,440
Unrealized loss from marketable securities	-158,507	0	-158,507	0
Comprehensive loss	($3,955,039)	($1,011,002)	($6,961,433)	($2,816,046)

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Common Stock Subscribed [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Loss [Member]
Balances at Dec. 31, 2012	($153,629)	$6,000	$27,367	$0	$1,711,673	($153,250)	($1,745,419)
Balances (in Shares) at Dec. 31, 2012		6,000,000	27,367,144
Issuance of common stock, net of issuance costs	4,486,541		2,115		4,484,426
Issuance of common stock, net of issuance costs (in Shares)			2,115,100
Cancellation of preferred stock		-3,000			3,000
Cancellation of preferred stock (in Shares)		-3,000,000
Proceeds from common stock subscribed					-138,250	138,250
Issuance of warrants for acquisition of Vaporfection	1,166,000				1,166,000
Issuance of common stock for accounts payable	119,553		44		119,509
Issuance of common stock for accounts payable (in Shares)			43,506
Capital contributions, related parties	810,000				810,000
Net loss	-3,791,440						-3,791,440
Balances at Dec. 31, 2013	2,637,025	3,000	29,526	0	8,156,358	-15,000	-5,536,859
Balances (in Shares) at Dec. 31, 2013		3,000,000	29,525,750
Issuance of common stock, net of issuance costs	2,427,859		486		2,427,373
Issuance of common stock, net of issuance costs (in Shares)			485,830
Stock-based compensation	1,031,640		93		1,031,547
Stock-based compensation (in Shares)			93,751
Proceeds from common stock subscribed	15,000					15,000
Unrealized loss from marketable securities	-158,507							-158,507
Treasury stock	-1,209,600			-1,209,600
Treasury stock (in Shares)				-60,000
Net loss	-6,802,926						-6,802,926
Balances at Sep. 30, 2014	($2,059,509)	$3,000	$30,105	($1,209,600)	$11,615,278	$0	($12,339,785)	($158,507)
Balances (in Shares) at Sep. 30, 2014		3,000,000	30,105,331	-60,000

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities
Net income (loss)	($6,802,926)	($2,816,046)
Adjustments to reconcile net income (loss) to net cash:
Depreciation and amortization	59,364	41,375
Provisions and allowances	60,000	0
Profit on sale of the investments	-9,600	0
Market value of securities received for services	-190,132	0
Gain from fair value adjustment of derivative liability	-548,315	0
Amortization of debt discount charged as interest expense	216,224	0
Stock based compensation	1,031,640	0
Changes in operating assets and liabilities
Accounts receivable	213,424	598,906
Loan receivable	0	-55,000
Inventories	110,788	-135,888
Prepaid expenses and other assets	-896,954	-177,287
Accounts payable and accrued expenses	907,684	-232,727
Customer deposits	807,347	517,675
Deferred revenue	390,311	-783,899
Net cash used in operating activities	-4,651,146	-3,042,891
Cash flows from investing activities
Issuance of note receivable	-115,000	0
Purchase of property and equipment, net	-32,982	-188,485
Purchase of real estate	-399,594	0
Purchase of intangible assets	-166,183	0
Advances for investments	0	-1,200,000
Net cash used in investing activities	-713,759	-1,388,485
Cash flows from financing activities
Related party notes payable, net	379,880	-934,035
Payments on long term loan	0	-62,280
Proceeds from issuance of notes payable	299,605	150,000
Proceeds from issuance of common stock, net	2,442,859	3,541,090
Proceeds from issuance of convertible notes payable	3,500,000	0
Contributions to capital, related party	0	810,000
Payments on notes payable	-75,000	0
Net cash provided by financing activities	6,547,344	3,504,775
Net increase in cash	1,182,439	-926,601
Cash, beginning of period	168,003	1,026,902
Cash, end of period	1,350,442	100,301
Supplemental disclosures of cash flow information:
Cash paid for interest	37,078	8,940
Cash paid for income taxes	0	9,068
Non - cash transactions:
Liabilities assumed for Vaporfection International, Inc.	0	469,000
Common stock warrants issued for Vaporfection International, Inc.	$0	$1,166,000

BUSINESS_ORGANIZATION_NATURE_O

BUSINESS ORGANIZATION, NATURE OF OPERATIONS	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]
BUSINESS ORGANIZATION, NATURE OF OPERATIONS	NOTE 1 – BUSINESS ORGANIZATION, NATURE OF OPERATIONS
	Medbox, Inc. (the “Company”) was incorporated in the state of Nevada on June 16, 1977, originally as Rabatco, Inc., subsequently changing its name on May 12, 2000 to Mindful Eye, Inc., and again on August 30, 2011 to Medbox, Inc. The Company, through its subsidiaries, provides consulting and real estate management services and products for the medical and retail industries. The Company also sells patented biometrically controlled medicine storage and dispensing systems and a line of vaporizer and accessory products. The Company additionally provides management oversight and compliance services for retail dispensaries and cultivation facilities and procures real estate and enters into leases for retail dispensaries and cultivation centers. The Company is headquartered in West Hollywood, California with offices in Arizona and Florida.
	During nine months ended September 30, 2014 the Company formed eight new subsidiaries, as follows:
		•	Medbox CBD, Inc., specializing in hemp-oil concentrates and development of pharmaceutical products derived from cannabis to produce and distribute products based upon lifting of federal prohibitions of such activities.
		•	Medbox Property Investments, Inc., specializing in real property acquisitions and leases to dispensaries and cultivation centers.
		•	MJ Property Investments, Inc. specializing in real property acquisitions and leases to retail stores and cultivation centers in the state of Washington. (This is a wholly owned subsidiary of Medbox Property Investments, Inc.)
		•	Medbox Management Services, Inc., a California corporation specializing in dispensary management services to state licensed dispensaries for cultivation, dispensing, and marijuana infused products (MIPS).
		•	Medbox Merchant Service, Inc., specializing in banking transactions with prepaid debit cards, convenience checks, and cash depository needs for operators. This subsidiary is current inactive.
		•	Medbox Armored Transport, Inc., specializing in armored car transport of cash from dispensaries to participating banks. This subsidiary is current inactive.
		•	Medbox Investments, Inc., specializing in investments and strategic partnerships in other public companies in the marijuana ancillary service sector that Medbox believes are viable and have growth potential.
		•	Medbox Management Services, Inc., a Nevada corporation specializing in dispensary management services to state licensed dispensaries for cultivation, dispensing, and marijuana infused products.
		•	Medbox Management Services, Inc., an Illinois corporation specializing in dispensary management services to state licensed dispensaries for cultivation, dispensing, and marijuana infused products.
	In order to obtain the license for one of the Company’s clients the Company registered an affiliated nonprofit corporation Allied Patient Care, Inc. in the state of Oregon.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (RESTATED)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (RESTATED)	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (RESTATED)
	Principles of Consolidation
	The consolidated financial statements include the accounts of Medbox, Inc. and its wholly owned subsidiaries. All intercompany transactions have been eliminated.
	Use of Estimates
	The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the condensed consolidated financial statements as well as the reported expenses during the reporting periods. The Company’s significant estimates and assumptions include the valuation of the Company’s common stock used in the valuation of goodwill, accounts receivable and note receivable collectability, inventory, advances on investments, the valuation of restricted stock and warrants received from customers, the amortization and recoverability of capitalized patent costs and useful lives of long-lived assets the derivative liability, and income tax expense. Some of these judgments can be subjective and complex, and, consequently, actual results may differ from these estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from these estimates.
	Concentrations of Credit Risk (Restated)
	The Company maintains cash balances at several financial institutions in the Los Angeles, California area and Florida. Accounts at each institution are insured by the Federal Deposit Insurance Corporation up to $250,000. At September 30, 2014 and December 31, 2013, the Company’s uninsured balances totaled $967,347 and $0, respectively. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible.
	At September 30, 2014, one customer, represented 77.4% of outstanding receivables
		September 30, 2014						January -					December 31, 2013					January -
								September 2014										September 2013
		Accounts						Revenue					Accounts					Revenue
		Receivable											Receivable
		Amount,			%			Amount,		%			Amount,		%			Amount,		%
		$						$					$					$
	A		—			—			190,131		32.5	%		150,000		44.2	%		325,000		17.6	%
	B		—			—			175,000		30	%		115,200		33.9	%
	C		25,000			77.4	%		—		—
	D
	E
			25,000			77.4	%		365,131		62.5	%		265,200		78.1	%		325,000		17.6	%
	Total		32,312			100	%		584,191		100	%		339,736		100	%		1,844,376		100	%
	Advertising and Marketing Costs
	Advertising and marketing costs are expensed as incurred. The Company incurred advertising and marketing costs of $319,204 and $91,136 for the three months ended September 30, 2014 and 2013, and $749,212 and $506,393 for the nine months ended September 30, 2014 and 2013, respectively.
	Research and Development
	Research and development expenses are charged to operations as incurred. The Company incurred research and development costs of $61,623 and $28,233 for the three months ended September 30, 2014 and 2013, and $136,656 and $46,733 for the nine months ended September 30, 2014 and 2013, respectively.
	Fair Value of Financial Instruments
	Pursuant to ASC No. 825, Financial Instruments, the Company is required to estimate the fair value of all financial instruments included on its balance sheets. The carrying value of cash, accounts receivable, other receivables, inventory, accounts payable and accrued expenses and notes payable, related party notes payable, customer deposits, provision for customer refunds and short term loans payable approximate their fair value due to the short period to maturity of these instruments. The Company’s marketable securities and related customer deposits require fair value measurement on a recurring basis as the Company has received advance payment of restricted stock in a publicly traded company for contracted services and received warrants for service provided to unrelated third party. The Company has no exposure to gain or loss on the increase or decrease in the value of the marketable securities received as a payment from customer as any shortfall in the ultimate liquidated value of the securities will be supplemented by additional restricted stock from the customer and any liquidation in excess above the Company’s billings will be returned to the customer. The securities received as a payment for services provided will be exposed to gains or losses following their initial evaluation as of the date the revenue was earned.
	Warrants and other financial assets received as a payment for the services provided are recorded as “Marketable securities” under the current assets if they are expected to be realized within 12 months. The Company uses the Black-Scholes model to measure the value of the warrants. At each reporting date the Company will reevaluate the value of marketable securities and record any changes in value to other comprehensive income (loss) under “Unrealized gain or losses from marketable securities”.
	Embedded derivative - The Company’s convertible notes payable include embedded features that require bifurcation and are accounted for as a separate embedded derivative (see Note 13). The Company has estimated the fair market value of the embedded derivative of the Notes as the difference between the fair market value of the Notes with the conversion feature and the fair market value of the Notes without the conversion feature associated with the embedded derivative, in both cases using relevant market data. In the case of the fair market value of the Notes with the conversion feature, a binomial lattice model was used utilizing a discount rate based on variable conversion probability. In the case of the fair market value of the Notes without the conversion feature associated with the embedded derivative, a discounted cash flow approach was used. The key valuation assumptions used consist of the price of the Company’s stock, a risk free interest rate based on the average yield of a one year Treasury note and expected volatility of the Company’s common stock all as of the measurement dates. The Company considers these inputs Level 3 assumptions.
	A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:
	Level 1	Quoted prices in active markets for identical assets or liabilities.
	Level 2	Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly.
	Level 3	Significant unobservable inputs that cannot be corroborated by market data.
	The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the liabilities that are measured at fair value on a recurring basis.
		Total			Quoted Prices			Quoted Prices		Significant
					in Active			for Similar		Unobservable
					Markets for			Assets or		Inputs
					Identical			Liabilities in		(Level 3)
					Assets or			Active
					Liabilities			Markets
					(Level 1)			(Level 2)
	September 30, 2014
	Marketable securities	$	208,025		$	208,025		$	—	$	—
	Conversion Feature		1,228,108			—			—		1,228,108
	Total	$	1,436,133		$	208,025		$	—	$	1,228,108
	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis:
		For the nine months
		ended
		September 30, 2014
		Total
	Beginning balance	$	—
	Initial recognition of conversion feature		1,776,423
	Change in fair value of conversion feature		(548,315	)
	Ending balance	$	1,228,108
	Revenue Recognition (Restated)
	The Company applies the revenue recognition provisions pursuant to ASC No. 605, Revenue Recognition, which provides guidance on the recognition, presentation and disclosure of revenue in financial statements filed with the SEC. The guidance outlines the basic criteria that must be met to recognize the revenue and provides guidance for disclosure related to revenue recognition policies.
	Revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonably assured. For multi-year contracts with upfront payments made by customers, the upfront payments are recognized over the longer of the contract period or the customer relationship. For contracts that include multiple deliverables such as the build out of customer facilities, the Company recognizes revenue when a milestone is reached in the contract such as securing the location, delivery of dispensing machines or completion of the facility. The contract terms are broken down in specific milestones with specific attributable revenue to be earned upon successful completion of the milestone terms – ( e.g – if a milestone is completing construction on a client dispensary, the condition for the revenue to be recorded is after issuance of a certificate of occupancy for the newly completed facility). The Company will record a specified amount of revenue attributable to this milestone based on the contract). Equipment sales not associated with a consulting contract are recognized as the product is shipped and title passes. Advance payments from clients in advance of work performed are recorded as customer deposits on the balance sheet.
	An allowance for bad debt is established for any customer when their balance is deemed as possibly uncollectible.
	Provisions for estimated returns and allowances, and other adjustments are usually provided in the same period the related sales are recorded. The Company will at times allow customers to receive full refunds should regulatory events prevent the customer from being able to operate his contracted location. The provision for returns as well as an allowance for doubtful accounts is included in the Company’s balance sheet as determined by management.
	Provisions for estimated returns and allowances, and other adjustments are provided in the same period the related sales are recorded. The Company will at times allow customers to get full refunds should political events prevent the customer from being able to operate his or her contracted location. The provision for returns as well as an allowance for bad debts will be included in the Company’s balance sheet should the Company deem such allowances justified.
	Cost of Revenues (Restated)
	Cost of revenue consists primarily of expenses associated with the delivery and distribution of our products and services. These include expenses related to the manufacture of our dispensary units, construction expense related to the customer dispensary, site selection and establishment of licensing requirements, and consulting expense for the continued management of the dispensary unit build out, server and security equipment, rent expense, energy and bandwidth costs, and support and maintenance costs prior to when the client moves in. We only begin capitalizing costs when we have obtained a license and a site for operation of a customer dispensary or cultivation center. The previously capitalized costs are charged to cost of revenue in the same period that the associated revenue is earned. In the case where it is determined that previously inventoried costs are in excess of the projected net realizable value of the sale of the licenses then the excess cost above net realizable value is written off to cost of revenues. In addition, cost of revenue related to our vaporizer line of products consists of direct procurement cost of the products along with costs associated with order fulfillment, shipping, inventory storage and inventory management costs.
	Basic and Fully Diluted Net Income/Loss Per Share
	Basic net income/loss per share is computed by dividing net income/loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net incomes per share include the effects of any outstanding options, warrants and other potentially dilutive securities. The Company did not consider any potentially dilutive common shares in the computation of diluted loss per share for the periods ending September 30, 2014 and December 31, 2013, due to the net loss, as they would have an anti-dilutive effect on EPS.
As of September 30, 2014 and December 31, 2013, the Company had 3,000,000 shares of Series A preferred stock outstanding with par value of $0.001 that could be converted into 15,000,000 shares of the Company’s common stock. The Company also had 295,854 warrants to purchase common stock outstanding as of September 30, 2014.
Accounts Receivable and Allowance for Bad Debts (Restated)
The Company is subject to credit risk as it extends credit to our customers for work performed as specified in individual contracts. The Company extends credit to its customers, mostly on an unsecured basis after performing certain credit analysis. Our typical terms require the customer to pay a portion of the contract price up front and the rest upon certain agreed milestones. The Company’s management periodically reviews the creditworthiness of its customers and provides for probable uncollectible amounts through a charge to operations and a credit to an allowance for doubtful accounts based on our assessment of the current status of individual accounts. Accounts still outstanding after the Company has used reasonable collection efforts are written off through a charge to the allowance for doubtful accounts. As of September 30, 2014 and December 31, 2013, the Company’s management considered all accounts outstanding fully collectible.
Property and Equipment
Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses accelerated depreciation methods for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows:
Vehicles	5 years
Furniture and Fixtures	5 years
Office equipment	3 years
Assets Held for Resale
During 2014, the Company has entered into various real estate purchase agreements to support the filing of retail dispensary or cultivation facility licenses in certain states and localities. The cost of the acquired real estate is included in Assets Held for Resale on the balance sheet. The Company intends to sell the real estate to a long term investor after the license is granted. Accordingly, the company does not depreciate assets held for resale.
Income Taxes
The Company accounts for income taxes under the asset and liability method in accordance with ASC 740. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities are classified as current and non-current based on their characteristics. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.
In addition, the Company’s management performs an evaluation of all uncertain income tax positions taken or expected to be taken in the course of preparing the Company’s income tax returns to determine whether the income tax positions meet a “more likely than not” standard of being sustained under examination by the applicable taxing authorizes. This evaluation is required to be performed for all open tax years, as defined by the various statutes of limitations, for federal and state purposes.
Commitments and Contingencies
Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.
If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.
Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.
Recent Accounting Pronouncements
There were various accounting updates recently issued which are not expected to a have a material impact on the Company’s consolidated financial position, consolidated results of operations or cash flows.

ACQUISITION

ACQUISITION	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]
ACQUISITION	NOTE 3 – ACQUISITION
	On March 22, 2013, the Company entered into a purchase agreement for 100% of the issued and outstanding common stock of Vaporfection International Inc. (“VII”) owned by Vapor Systems International LLC. The Company closed the transaction on April 1, 2013. The Company issued 260,854 warrants to shareholders of VII allowing them to purchase one (1) share of Medbox common stock at $.001 per share beginning April 1, 2013. These warrants were valued for the Company’s accounting purposes at $4.47 per share which represented the fair value of the Company’s common stock as determined by the Company’s independent appraiser. In addition, the Company assumed certain liabilities and a 10% convertible note of VII in the aggregate amount of approximately $470,000. The total value of the acquisition was approximately $1,635,000 and has been allocated in accordance with ASC 805 as per the Company’s independent valuation as follows:
	Machinery & Equipment	$	70,000
	IP and related technology		287,000
	Amortizable intangible assets:
	Customer contracts and related relationships		314,000
	Trade name, trademark, and domain name		46,000
	Non-compete covenants		23,000
	Goodwill		895,000
	Total assets acquired		1,635,000
	Fair value of liabilities assumed		(469,000	)
	Net fair value	$	1,166,000
	The amortizable intangible assets have useful lives not exceeding ten years. No amounts have been allocated to in-process research and development and $895,000 was originally allocated to goodwill. In addition, from the date of acquisition through March 31, 2014 and December 31, 2013, the liabilities assumed have been increased by approximately $10,000 and $195,000 respectively as they have been accrued or settled. No additional adjustments to Goodwill occurred in the six months ended September 30, 2014. Accordingly, $205,000 has also been allocated to goodwill. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and is not deductible for tax purposes.
	The number of warrants available to selling VII shareholders was increased by 130,427 shares in connection with a settlement with such former VII shareholders.
	In addition to the above warrants, the purchase agreement and associated consulting contract with the prior management company of the business unit calls for additional shares of common stock to be issued in the event that the performance of the business unit exceeds $11,818,140 of accumulated EBITBA over the subsequent 4 year operating period. The performance payout is contingent upon future events and accordingly the Company has treated the obtainment of that performance provision as being remote and consequently has not assigned any future value to the purchase price.

INVESTMENTS

INVESTMENTS	9 Months Ended
	Sep. 30, 2014
Investments Schedule [Abstract]
INVESTMENTS	NOTE 4 – INVESTMENTS
	On February 8, 2013, the Company entered into an agreement with Bio-Tech Medical Software, Inc. (“Bio-Tech”) which would allow the Company to purchase 833,333 shares of common stock which would represent 25% of Bio-Tech’s issued and outstanding shares of common stock for $1,500,000. The Company advanced $600,000 upon execution of this agreement for the right to purchase with the remaining balance of $900,000 due and payable in installments at various dates by August 25, 2013. On June 26, 2013, the Company notified Bio-Tech that it was canceling the agreement.
	On February 27, 2014, the Company signed a settlement agreement, and in connection therewith, a second amended and restated technology license agreement with Bio-Tech. Pursuant to the second amended and restated technology license agreement, the Company received full licensed right to biometric inventory tracking technology for the term of five years with no additional monies due. All stock transfer between companies was canceled and rescinded.
	On June 5, 2014 the Company entered into a sale agreement with an affiliate company owned by the co-founder of the Company for the sale of all Bio-Tech rights and claims and a contribution for legal costs of $4,800 in exchange for the return of 30,000 shares of the Company’s common stock with a fair value of $604,800. These shares are treated as treasury stock and can be reissued.
	On March 12, 2013, the Company entered into an agreement with three members of MedVend Holdings LLC (“MedVend”) whereby the Company would acquire 50% of their equity interest in MedVend. The purchase price of the equity interest was $4,100,000. The Company paid an advance of $300,000 upon execution of the contract for the right to purchase and another $300,000 was disbursed as an additional investment to MedVend. In May 2013, the three members of MedVend were named in a lawsuit by that entity’s minority shareholders alleging improper conveyance of the three members’ ownership interest in MedVend to the Company. Accordingly, also in May 2013, Medbox filed suit against MedVend and the three members of that entity that were involved in the transaction.
	On June 5, 2014 the Company entered into a sale agreement with an affiliate company owned by the co-founder of the Company for the sale of all the MedVend rights and claims and a contribution for legal costs of $4,800 in exchange for 30,000 shares of the Company’s common stock with a fair value of $604,800. These shares are treated as treasury stock and can be reissued.
	The shares of common stock received for the Bio-Tech and MedVend sales to the affiliate company are recorded as treasury stock at cost of $1,209,600 for 60,000 shares.

INVENTORIES_Restated

INVENTORIES (Restated)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]
INVENTORIES (Restated)	NOTE 5 – INVENTORIES (RESTATED)
	Inventories are stated at the lower of cost or market value. Cost is determined on a standard cost basis that approximates the first-in, first-out (FIFO) method.
	The consolidated inventories at September 30, 2014 and December 31, 2013 consist of the following:
		September 30, 2014		December 31, 2013
		(Restated)
	Work in process and related capitalized costs	$	—	$	242,488
	Deposits on dispensing machines		336,583		138,423
	Vaporizers and accessories		164,030		193,575
	Dispensing machines		21,585		58,500
	Total inventory, net	$	522,198	$	632,986
	During the third quarter of 2014 the Company wrote down slow moving, older models of vaporizer inventory with a charge to cost of revenue of $329,154.

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 6 – PROPERTY AND EQUIPMENT
	Property and equipment at September 30, 2014 and December 31, 2013 consists of:
	Property and Equipment	September 30, 2014			December 31, 2013
	Office equipment	$	22,934		$	17,192
	Furniture and fixtures		74,404			73,567
	Website development		46,922			46,922
	Product tooling		50,503			24,100
			194,763			161,781
	Less accumulated depreciation		(42,779	)		(21,123	)
	Property and equipment, net	$	151,984		$	140,658
	Product tooling costs are related to the tooling of a new product by VII. These tooling costs are accumulated and capitalized until launch date of the new product which is expected to commence in the fourth quarter of 2014.

ASSETS_HELD_FOR_RESALE

ASSETS HELD FOR RESALE	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]
ASSETS HELD FOR RESALE	NOTE 7 – ASSETS HELD FOR RESALE
	In the course of seeking licenses for new locations, the Company has to enter into real estate purchase agreements in order to secure the sites to be developed for clients’ dispensaries and cultivation centers. The Company intends to close on the real estate where purchase agreements have been signed, or to seek partners to replace the Company on each property purchased. During the second quarter of 2014 one of the Company’s subsidiaries entered into a real estate purchase agreement in Washington state. The purchase transaction was closed during the third quarter for a total purchase price of $399,594 partially financed by a promissory note for $249,000. The note bears an interest rate of 12% per year and matures on January 30, 2015. The interest is payable monthly in the amount of $2,490 for six months from the execution date, which was July 28, 2014. In the event of a default, as defined, the interest rate increases to 18% and the note can be accelerated.
	Assets held for resale	September 30, 2014		December 31, 2013
	Buildings held for resale	$	399,594	$	—
	Assets held for resale	$	399,594	$	—

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 8 – INTANGIBLE ASSETS
	The Company acquired certain intangible assets with its purchase of 100% of the outstanding common stock of VII on March 22, 2013. The Company accounts for intangible assets acquired in a business combination, if any, under the purchase method of accounting at their estimated fair values at the date of acquisition. Intangibles are either amortized over their estimated lives, if a definite life is determined, or are not amortized if their life is considered indefinite.
	Intangible assets	September 30, 2014			December 31, 2013
	Distributor relationship	$	314,000		$	314,000
	IP/technology/patents		403,363			332,179
	Domain names		131,000			46,000
	Non-compete covenants		23,000			23,000
	Subtotal		871,363			715,179
	Less accumulated amortization		(70,459	)		(32,750	)
	Intangible assets, net	$	800,904		$	682,429
	The estimated useful lives for significant intangible assets are as follows:
	Distributor Relationship	10 years
	Domain Names	10 years
	IP/Technology/Patents	10 years
	Non-Compete covenants	3 years
	The Company’s management does not believe any impairment of intangible assets has occurred as of September 30, 2014.

ACCOUNTS_AND_NOTES_RECEIVABLE_

ACCOUNTS AND NOTES RECEIVABLE (RESTATED)	9 Months Ended
	Sep. 30, 2014
Receivables [Abstract]
ACCOUNTS AND NOTES RECEIVABLE (RESTATED)	NOTE 9 – ACCOUNTS AND NOTES RECEIVABLE (RESTATED)
	Accounts receivables
	Periodically the Company assesses and reviews the receivables for collectability. As of September 30, 2014 and December 31, 2013, the Company’s management considered all accounts outstanding fully collectible.
	Notes Receivable current
	During the third quarter of 2014 one of the Company’s clients signed a note for $75,000 as a payment on accounts receivable. The note is due on December 31, 2014 and bears an interest rate of 7.5%.
	Notes Receivable non-current
	During December 2013, the Company entered into a multiple advance secured promissory note for $1,000,000 with a Canadian partner, all transactions with whom are considered to be on an arms-length basis. This note is due and payable, together with interest at 5% per annum on December 10, 2018. As of September 30, 2014 and December 31, 2013 the outstanding balance of this note receivable was $155,000 and $115,000 respectively.

MARKETABLE_SECURITIES

MARKETABLE SECURITIES	9 Months Ended
	Sep. 30, 2014
Investments, Debt and Equity Securities [Abstract]
MARKETABLE SECURITIES	NOTE 10 – MARKETABLE SECURITIES
	Marketable securities of the Company represent the shares received as a payment from clients for services provided.
	Marketable securities	Value as of		Value as of
		September 30, 2014		December 30, 2013
	Shares received as a payment from client	$	176,400	$	184,800
	Securities from MJ Holdings, Inc.		31,625		—
	Total marketable securities	$	208,025	$	184,800
	As of September 30, 2014 and December 31, 2013 the fair value of these marketable securities was $208,025 and $184,800, respectively.
	As of September 30, 2014, the Company held as a deposit 7,000,000 restricted shares (issued on September 5, 2013) as payment for $300,000 in accounts receivable billed to a customer. The fair value of the shares as of September 30, 2014 and December 31, 2013 (with 12% restricted stock discount as of December 31, 2013 and without a discount at September 30, 2014 because the restriction lapsed in 2014) was $176,400 and $184,800, respectively. The value of these unliquidated shares is offset against the outstanding amounts owed to the Company up to $300,000 (the value of receivable of the client) until such time that the shares are liquidated and only at that time that the cash proceeds are used to pay off the receivable will any excess cash received be returned to the client in accordance with the contract.
	On May 19, 2014 the Company entered into an agreement with MJ Holdings, Inc., a publicly traded company that provides real estate financing and related solutions to licensed marijuana operators. The Company will market MJ Holdings’ real estate financial products and offerings to its consulting clients and will direct all incoming real estate related opportunities to MJ Holdings. Under the agreement, the Company will receive 50% of management fees and profits realized from the real estate opportunities it presents, in addition to warrants to purchase shares in MJ Holdings. The initial term of the agreement is six months, and will renew automatically for successive one month terms, unless one of the parties notifies the other in writing of its the intention to terminate the agreement. MJ Holdings, Inc. agreed to issue to the Company, for this six month term of the contract, 33,333 warrants to purchase common stock on each month’s anniversary of the contract. As of September 30, 2014 the Company received five warrants for the services provided under the agreement. The following table represents the initial recognition value and subsequent adjustment as of reporting date:
	Warrants	Initial Fair		Fair Value at			Gain or (Loss)			Fair Value as of
		Value		Conversion						September 30,
										2014
	Warrant #1	$	95,866	$	(94,719	)	$	(1,147	)	$	—
	Conversion of the Warrant #1 to 10,825 shares		—		94,719			(72,961	)		21,758
	Warrant #2		2,666					(2,033	)		633
	Warrant #3		53,867					(53,033	)		834
	Warrant #4		30,600					(29,333	)		1,267
	Warrant #5		7,133					—			7,133
	Total	$	190,132	$	—		$	(158,507	)	$	31,625
	At initial recognition the value of warrants is recorded as “Marketable securities” and “Revenue” for services provided. Subsequent to initial recognition all valuation adjustments are reflected through other comprehensive income (loss) as “Unrealized gain or losses from marketable securities”. In June 2014, warrant #1 was converted to 10,825 shares of MJ Holdings common stock through the cashless exercise option. The fair value of the shares as of September 30, 2014 was $21,758. The Company uses the published closing price of the stock to value the stock held by the Company.
	The Company uses a Black-Scholes model to measure the value of the warrants. The following data were introduced in the model in order to assess the value of the warrants assuming that the Company expects to keep the warrants for six months:
	Black-Scholes Calculator Data	Initial Valuation and Recognition
		#1		#2			#3			#4		#5
	Warrant
	Stock price, $		8.69		4			8			6.15		2.01
	Exercise price, $		6.41503521		8.454933			7.874619			6.953694		3.53412
	Time to maturity, Years		0.5		0.5			0.5			0.5		1
	Annual risk-free rate, %		0.05		0.05			0.05			0.05		0.04
	Annualized volatility, %		70		70			70			70		70
	Black-Scholes Value per warrant, $		2.876		0.08			1.616			0.918		0.214
	Number of warrants/shares		33,333		33,333			33,333			33,333		33,333
	Total value of warrants/shares, $		95,866		2,666			53,867			30,600		7,133
	The following data were used by the company for the Black-Scholes model valuation of the warrants as of September 30, 2014:
	Fair Value of Warrants	As of September 30, 2014
		#2		#3			#4			#5
	Warrant
	Stock price, $		2.01		2.01			2.01			2.01
	Exercise price, $		8.454933		7.874619			6.953694			3.53412
	Time to maturity, Years		1		1			1			1
	Annual risk-free rate, %		0.13		0.13			0.13			0.13
	Annualized volatility, %		70		70			70			70
	Black-Scholes Value per warrant, $		0.019		0.025			0.038			0.214
	Number of warrants/shares		33,333		33,333			33,333			33,333
	Total value of warrants/shares, $		633		834			1,267			7,133

CUSTOMER_DEPOSITS_RESTATED

CUSTOMER DEPOSITS (RESTATED)	9 Months Ended
	Sep. 30, 2014
Banking and Thrift [Abstract]
CUSTOMER DEPOSITS (RESTATED)	NOTE 11 – CUSTOMER DEPOSITS (RESTATED)
	Advance payments from customers are recorded as customer deposits on the balance sheet.
	Customer deposits	September 30, 2014		December 31, 2013
		(Restated)
	Advance payments from customers	$	1,509,770	$	710,225
	Advance payments for vaporizers		75,038		75,636
	Total customer deposits	$	1,584,808	$	785,861

SHORTTERM_DEBT

SHORT-TERM DEBT	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]
SHORT-TERM DEBT	NOTE 12 – SHORT-TERM DEBT
	Short-term debt as of September 30, 2014 and December 31, 2013 consisted of:
	Short-term debt	September 30, 2014		December 31, 2013
	Notes payable to unrelated third party	$	299,605	$	75,000
	Notes payable to related party		491,674		111,794
	Total short-term debt	$	791,279	$	186,794
	On July 28, 2014 one of the Company’s subsidiaries executed a promissory note for $249,000 for the purchase of real estate (also see note 7). The note matures on January 30, 2015 and bears 12.0% interest annually. The interest is payable monthly starting August 1, 2014 with a final, sixth payment on January 1, 2015. In the event of a default, as defined, the interest rate increases to 18% and the note can be accelerated. The December 31, 2013 balance of the $75,000 note payable to an unrelated third party was paid in full during nine months of 2014. The notes payable to related parties bear no interest.
	The short term loan represents the outstanding balance in the amount of $50,605 of the financing in the amount of $137,160 for the Directors’ & Officers’ (D&O) liability insurance and $22,160 for product liability insurance. The financing of D&O insurance bears 4.25% interest and is payable in monthly payments of $15,511 for nine months with the first payment due on March 5, 2014 and the last payment due on November 5, 2014. The financing of product liability insurance bears 5.99% interest and is payable in monthly payments of $2,524 for nine months with the first payment due on September 5, 2014 and the last payment due on May 5, 2015.

CONVERTIBLE_NOTES_PAYABLE_AND_

CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY	NOTE 13 – CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY
	On July 21, 2014, as amended on September 19, 2014 and October 20, 2014, the Company entered into a Securities Purchase Agreement whereby the Company agreed to issue convertible debentures (“July 2014 Purchase Agreement Debentures”) in the aggregate principal amount of $3,500,000, in five tranches. The initial closing in the aggregate principal amount of $1,000,000 occurred on July 21, 2014. The second closing in the amount of $1,000,000 occurred on August 26, 2014; the third of $500,000 on September 26, 2014. The fourth and fifth, each in the amount of $500,000, are to occur within 2 and 5 business days, respectively, of the effective date of the registration statement filed by the Company for the resale of the shares of common stock issuable upon conversion of the July 2014 Purchase Agreement Debentures. The July 2014 Purchase Agreement Debentures bear interest at the rate of 10% per year. The debt is due July 21, 2015, with repayment, including accrued principal and accrued interest, beginning on the eleventh day of the fourth month after issuance and will continue on the eleventh day of each following 8 successive months thereafter.
	Also on September 19, 2014, as amended on October 20, 2014, the Company entered into a securities purchase agreement pursuant to which it agreed to issue convertible debentures (“September 2014 Purchase Agreement Debentures”) in the aggregate principal amount of $2,500,000, in two tranches. The initial closing in the principal amount of $1,000,000 occurred on September 19, 2014. The second closing, of $1,500,000, is to occur within 2 days of the effective date of the registration statement filed by the Company for the resale of the shares of common stock issuable upon conversion of the September 2014 Purchase Agreement Debentures. The September 2014 Purchase Agreement Debentures bear interest at the rate of 5% per year. The debt is due September 19, 2015, with repayment, including accrued principal and accrued interest, due in nine monthly installments, commencing the fourth month after issuance.
	Both the July 2014 Purchase Agreement Debentures and September 2014 Purchase Agreement Debentures, share the following significant terms:
	Conversion - All amounts are convertible at any time, in whole or in part, at the option of the holders into shares of the Company’s common stock at a conversion price, or Fixed Conversion Price, which is subject to adjustment as described below.
	The Notes are initially convertible into shares of the Company’s common stock at the initial Fixed Conversion Price of $11.75 per share. The Fixed Conversion Price is subject to adjustment for stock splits, combinations or similar events. If the Company makes any subsequent equity sales (subject to certain exceptions), under which an effective price per share that is lower than the Fixed Conversion Price, then the conversion price will be reduced to equal such price. The July 2014 Securities Purchase Agreement exempts any sales pursuant to the September 2014 Purchase Agreement Debentures from the July 2014 Purchase Agreement Debentures conversion price adjustments.
	The Company may make payments on the debt in cash, prompting a 30% premium or, subject to certain conditions, in shares of common stock valued at 70% of the lowest volume weighted average price of the common stock for the 20 prior trading days. However, in the event the registration statement filed by the Company in connection with the respective purchase agreements is not effective within 120 days of the initial closing date under the July 2014 Purchase Agreement and 120 days of the initial closing date under the September 2014 Purchase Agreement, the July 2014 Purchase Agreement Debentures’ and the September 2014 Purchase Agreement Debentures’, respectively, conversion rate will be, during the period commencing 120 days after the initial closing date until the registration statement is effective, equal to 63% of the lowest volume weighted average price of the common stock for the 20 prior trading days. If the aforementioned registration statement is not effective within 160 days of the initial closing date, each of the debentures’ conversion rate will be, during the period commencing 160 days after the initial closing date until the registration statement is effective, equal to 60% of the lowest volume weighted average price of the common stock for the 20 prior trading days.
	In connection with each of the purchase agreements, the Company entered into a registration rights agreement with the respective investors, pursuant to which the Company agreed to file a registration statement for the resale of the shares of common stock issuable upon conversion of, or payable as principal and interest on, the respective debentures, within 45 days of the initial closing date under each agreement, and to have such registration statements declared effective within 120 days of the initial closing dates of each purchase agreement.
	The $3.5 million principal amount of the Notes were issued net of $227,500 debt origination costs and $1.776 million initial fair value of the embedded derivative. The conversion feature of the notes meets the definition of a derivative under ASC 815 and requires bifurcation and is accounted for as a separate embedded derivative. Therefore, initially the embedded derivative was recorded on the balance sheet as a derivative liability at its estimated fair value of $1.776 million and created a discount on the Notes that will be amortized over the life of the Notes using the effective interest rate method. The fair value of the embedded derivative will be measured and recorded at fair value each subsequent reporting period and changes in fair value will be recognized in the statement of operations as a gain or loss on derivative. See Note 2 Fair value measure for additional information on the fair value and gains or losses on the embedded derivative.

PREPAID_EXPENSES_AND_OTHER_CUR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	9 Months Ended
	Sep. 30, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 14 – PREPAID EXPENSES AND OTHER CURRENT ASSETS
	Prepaid expenses and other currents assets as of September 30, 2014 and December 31, 2013 consisted of:
	Prepaid expenses and other current assets	September 30,		December 31,
		2014		2013
	Prepaid expenses
	Deferred loan cost	$	196,250	$	—
	Rent		5,262		3,962
	Directors & officers insurance		77,645		—
	Professional fees		30,000		52,739
	Other vendors		68,750		32,540
	Other current assets
	Earnest money deposits, net		634,288		—
	Prepaid expenses and other current assets	$	1,012,195	$	89,241
	Deferred loan cost represents the cost to secure the convertible note payable financing in the third quarter of 2014. The deferred loan costs will be amortized to expense over the life of the loans.
	Earnest money deposits consist of amounts paid to open escrow accounts for the purchase of multiple properties to be used to develop retail dispensary or product cultivation facilities. Also it includes amounts paid to extend the closing dates on some purchase agreements.

RESTRICTED_STOCK_AND_RESTRICTE

RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs")	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs")	NOTE 15 – RESTRICTED STOCK AND RESTRICTED STOCK UNITS (“RSUs”)
	On July 23, 2014, in connection with the election of a new Chairman, President and CEO, the Company entered into a two year employment contract with the new CEO. Under the employment contract, the CEO received an award of RSU’s, to be issued within 90 days of the effective date of the Employment Agreement, under the Equity Incentive Plan adopted by the Company, in the amount of the greater (by value) of 50,000 shares of common stock or $500,000 of common stock based on the volume weighted average price for the 30 day period prior to the date of the grant. The Company also agreed to make an equal stock award to the CEO on each anniversary date of the employment agreement. The RSU’s vest immediately during each year of the employment contract. As of September 30, 2014, the fair value of the grant was $711,500 which is being amortized over the CEO’s one year service period.
	On August 21, 2014, the Compensation Committee of the Board of Directors granted Restricted Stock and RSU’s to two Board members who were elected to the Board on April 9, 2014. Under the award, the Directors received 346,875 shares of restricted stock and 121,875 RSU’s under which the holders have the right to receive 121,875 shares of common stock. The grant date fair value of the restricted stock was $3,607,500 and the grant date fair value of the RSU’s was $1,267,500. The restricted Stock and RSU’s vest over the remaining first year of the new Board members’ term ending on March 31, 2015. The fair value of the grant is being amortized over the period from the date of grant, August 21, 2014 to the end of the first year of the Board members’ term, March 31, 2015. Under the Board members’ contracts, additional grants will be made for the second year of the contract.
	A summary of the activity related to restricted stock and RSUs for the nine months ended September 30, 2014 is presented below:
	Restricted stock	Total shares			Grant date fair
					value
	Restricted stock non-vested at January 1, 2014		—		$	—
	Restricted stock granted		346,875			10.4
	Restricted stock vested		(178,125	)		10.4
	Restricted stock forfeited		—			—
	Restricted stock non-vested at September 30, 2014		168,750		$	10.4
	Restricted stock units (RSU’s)	Total shares			Grant date fair
					value
	Restricted stock non-vested at January 1, 2014		—		$	—
	Restricted stock granted		171,875			10.4
	Restricted stock vested		(115,625	)		10.4
	Restricted stock forfeited					—
	Restricted stock non-vested at September 30, 2014		56,250		$	10.4
	A summary of the expense related to restricted stock and RSUs for the three and nine months ended September 30, 2014 is presented below:
	Summary of the expense related to Restricted Stock and RSUs	Three months			Nine
		ended			months ended
		September 30,			September 30,
		2014			2014
	Restricted Stock	$	663,262		$	663,262
	RSU’s		368,378			368,378
	Total stock based compensation expense	$	1,031,640		$	1,031,640

RELATED_PARTY_TRANSACTIONS_RES

RELATED PARTY TRANSACTIONS (RESTATED)	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS (RESTATED)	NOTE 16 – RELATED PARTY TRANSACTIONS (RESTATED)
	The Company utilizes Vincent Chase Inc., which is a related party and 100% owned by a co-founder of the Company for management advisory and consulting services. During the nine months ended September 30, 2014, the Company incurred $150,000 for these services at the rate of $12,500 per month for the first half of 2014 and $25,000 for the three months ended September 30, 2014.
	During 2013, the Company issued two promissory notes payable to Vincent Chase Inc., on September 20, 2013 in the amount of $150,000 and on October 28, 2013 in the amount of $100,000. At December 31, 2013 the outstanding amount for the combined notes was $111,794. As of September 30, 2014 these notes were repaid in full.
	During the first nine months of 2014, the Company issued four notes payable to PVM International Inc. (“PVMI”), a related party which is 100% owned by a co-founder of the Company in the amounts of $250,000, $100,000, $500,000, and $375,000. These notes were subsequently partially repaid leaving $391,674 outstanding as of September 30, 2014. During the first nine months of 2014, the Company issued a notes payable to Vincent Chase, Inc., a related party which is 100% owned by a co-founder of the Company in the amounts of $100,000. The aggregate amount of outstanding notes payable to related parties as of September 30, 2014 was $491,674. The notes bear no interest and are payable on demand.
	On March 25, 2014, the Company completed a contract for management rights with a related party and shareholder in the amount of $400,000. Also, the same related party paid the Company $150,000 during the first quarter of 2014 on behalf of one of the related party’s partners. These amounts were recorded as deposits in the Company’s balance sheet. In addition, on March 28, 2014, the Company entered into an agreement with the same related party for territory rights in Colorado for $500,000. The agreement has a term of five years and, accordingly, the revenue will be recognized ratably over five year term.
	On October 9, 2014 the Company made a principal payment to PVMI for $3,197.
	On July 21, 2014, the Company also paid $75,000 to PVMI as a partial payment for advances made by PVMI for escrow deposits used to secure properties for possible license acquisition in the San Diego market area.
	The Company utilized Dr. Bruce Consulting which is a related party and 100% owned by one of Company’s major shareholders and former Chief Executive Officer for management consulting and advisory service. During the nine months ended September 30, 2014 the Company incurred expenses in the amount of $18,750 for consulting and advisory services to Dr. Bruce Consulting. The Company will pay an additional $12,500 for consulting services to be provided in November 2014.
	During the application process for dispensaries and cultivation centers in Illinois, which took place in September, 2014, Dr. Bruce Bedrick, a major shareholder, provided funding to the applicant entity in the amount of $500,000. This amount was returned by the applicant entity to Dr. Bruce Bedrick by September 30, 2014.
	During the third quarter of 2014 the CEO of the Company and the Chairman of the board, Mr. Guy Marsala received 20,000 shares from the founder and major shareholder of the Company out of his personal holdings to compensate Mr. Marsala for his performance. On October 24, 2014 the Compensation Committee of the Board of Directors recommended that shares be returned to the founder and issued by the Company as part of the yearly RSU grant. In November 2014, Mr. Marsala returned 20,000 shares to founder and major shareholder and 20,000 additional shares were approved to increase Mr. Marsala’s first year RSU grant from 50,000 RSU’s to 70,000 RSU’s. (for details see Note 19 – “Subsequent events”)
	During the third quarter of 2014, the Company created the following affiliated entities in connection with license applications: A. Hanna Growers, Inc., Herbal Choice of Illinois, Inc., Nature’s Treatment of Illinois, Inc., Green Blossom of Illinois, Inc., Midwestern Compassionate Care of Illinois, Inc., Midwestern Wellness Group of Illinois, Inc., Green Blossom, Inc., Nature’s Treatment, Inc. and Herbal Choice, Inc.

STOCKHOLDERS_EQUITY

STOCKHOLDER'S EQUITY	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]
STOCKHOLDER'S EQUITY	NOTE 17 – STOCKHOLDER’S EQUITY
	Preferred Stock
	In November 2011, the Company issued 6,000,000 shares of $0.001 par value Series A convertible preferred stock to the founder and a shareholder of the Company. This preferred stock can be converted to common stock at a ratio of 1 (one) share of Series A Preferred Stock to 5 (five) shares of common stock. In October 2012, 3,000,000 shares of Series A Preferred Stock were returned to the Company by the shareholder and reissued to the founder. In January 2013, the founder returned to the Company the 3,000,000 shares of Series A Preferred Stock and they were immediately cancelled. As of September 30, 2014, there are 3,000,000 shares of Series A Preferred Stock outstanding.
	Common Stock
	On June 5, 2014 the Company entered into two separate sale agreements with an affiliate company owned by the co-founder of the Company. One was for the sale of all Bio-Tech rights and claims and a contribution for legal costs of $4,800 in exchange for 30,000 shares of Company common stock with a fair value of $604,800 and another for the sale of all the MedVend rights and claims and a contribution for legal costs of $4,800 in exchange for 30,000 shares of Company common stock with a fair value of $604,800. These 60,000 shares of common stock are treated as treasury stock and can be reissued.
	During the first quarter of 2014, the Company issued 485,830 shares of common stock at the price of $5.00 per share, resulting in net cash proceeds of $2,427,859.
	On December 19, 2013 the Company declared a 1:1 common stock dividend on each share of outstanding common stock. This stock dividend aggregating 14,762,875 common shares was issued on February 3, 2014. Accordingly, the Company’s 2013 condensed consolidated financial statements have been retroactively stated to reflect the common stock dividend.
	On September 8, 2014 the Company issued 93,751 shares of common stock to two board members from a total grant of 346,875 awarded by the Compensation Committee to board members.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 18 – COMMITMENTS AND CONTINGENCIES
	The Company leases property for its day to day operations and has recently begun leasing facilities for possible retail dispensary locations and cultivation locations as part of the process of applying for retail dispensary and cultivation licenses.
	Office Leases
	On August 1, 2011, the Company entered into a lease agreement for office space located in West Hollywood, California through June 30, 2017 at a monthly rate of $14,397. Starting July 1, 2014, the monthly rent increased by 3% to $14,828 per month.
	In addition, the Company leases office facilities located at West Hills, California and Scottsdale, Arizona from unrelated third parties at a monthly rate of $1,300 and $1,420. The West Hills lease is on a month to month basis. The Arizona lease is a non-auto renewing lease with the most current agreement covering the period from May 1, 2014 to October 31, 2014. The company terminated the West Hills and Scottsdale leases effective November 1, 2014.
	On December 17, 2013 the Company’s subsidiary Vaporfection International Inc. entered into a 1 year non-cancelable office lease in Deerfield Beach, Florida. The lease started on January 1, 2014 at a monthly rate of $1,981. After December 31, 2014 the lease converts to a month to month basis.
	The Company rents virtual offices/meeting spaces in Tokyo, New York, Toronto and Seattle on a month to month basis for an aggregate of approximately $390 per month. The payment is charged to rent expense as incurred.
	Total rent expense under operating leases for the three months ended September 30, 2014 and 2013 was $53,114 and $48,069, and for the nine months ended September 30, 2014 and 2013 was $156,716 and $91,983,.
	Retail/Cultivation facility leases
	The Company’s business model of acquiring retail dispensary and cultivation licenses has made it important to acquire real estate either through lease arrangements or through purchase agreements in order to secure a possible license. On May 8, 2014, the Company entered into a lease agreement for five years with a monthly payment of $7,400 in order to apply for a license and build-out of a location for a client. Also, on July 22, 2014 one of the Company’s subsidiaries Medbox Property Investments, Inc., entered into a new lease for a facility which will be used in the application process for both a dispensary and cultivation facility. The company paid an initial security deposit of $30,000 and the lease is payable monthly at a rate of $20,000 per month. The lease has a five year term, but is contingent upon license approval which allows for early termination of the lease after January 1, 2015 if the license is not granted.
	The following table is a summary of our material contractual lease commitments as of September 30, 2014:
	Year Ending	Office Rent		Retail/Cultivation
				Facility Lease
	2014	$	44,484	$	22,200
	2015		177,936		88,800
	2016		177,936		88,800
	2017		88,968		88,800
	2018		—		88,800
	2019		—		29,600
	Total	$	489,324	$	407,000
	Real Estate Commitments
	As part of the changes in the Company’s business model, the Company entered in various real estate purchase agreements at various times in order to allow the filing of retail dispensary or cultivation facility licenses in certain states and localities. These purchase agreements generally provide for a period of due diligence and a termination clause in the event that the Company is unable to obtain a license for its client. The agreements generally also provide for some monthly payment from escrow in order to compensate the real estate owner for the passage of time until the sale transaction is complete. Most of these payment releases from escrow are nonrefundable but applicable towards the purchase price if the Company decides to proceed with the purchase. Subject to approval of the license for a dispensary or cultivation center, the Company intends to close on the real estate where purchase agreements have been signed, or to seek partners to replace the Company on each property purchased.
	During the nine months period ended September 30, 2014 the Company paid $634,288 either by deposit into twelve escrow accounts or direct payments to sellers, to secure the purchase and/or extend the closing dates on real estate to be used for future retail/cultivation facilities with an aggregate purchase price of $23,030,000. The real estate purchase agreements have closing dates varying between December 1, 2014 and February 10, 2015.
	During the second quarter of 2014 one of the Company’s subsidiaries entered into a real estate purchase agreement in Washington state. The purchase transaction was closed during the third quarter for a total purchase price of $399,594 partially financed by a promissory note for $249,000.
	During July 2014 one of the real estate properties that MJ Property Investments, Inc. opened escrow on was foreclosed upon and the agreement was canceled and escrow money in the amount of $10,000 was reimbursed to the Company on July 28, 2014.
	During July 2014, MJ Property Investments, Inc. allowed the escrows to expire on two agreements with an aggregate purchase price of $2,500,000 and forfeited $100,000 in earnest money due to unfavorable terms demanded by the sellers to extend the escrow and closing date.
	A summary of open real estate purchase transactions as of September 30, 2014 is represented in the table below:
	Property	Purchase price		Closing		Net escrow balance		Date		Additional
				date				escrow opened		rents/fees paid to
										extend closing
										date
	1	$	3,500,000		12/11/14	$	60,000		7/25/14	$	—
	2		3,650,000		1/5/15		35,000		7/21/14		—
	3		2,450,000		12/1/14		80,000		8/13/14		—
	4		790,000		1/1/15		24,288		8/12/14		—
	5		480,000		1/31/15		16,000		8/12/14		—
	6		2,100,000		2/10/15		90,000		8/13/14		—
	7		595,000		1/31/15		10,000		8/13/14		—
	8		3,250,000		2/10/15		90,000		8/19/14		—
	9		2,400,000		2/8/15		19,000		8/19/14		—
	10		2,300,000		1/8/15		80,000		8/19/14		—
	11		695,000		10/18/14		10,000		6/28/14		—
	12		820,000		10/18/14		45,000		6/28/14		7,893
	13		—				75,000		7/21/14		—
	Total	$	23,030,000			$	634,288			$	7,893
	Property 13 represents the advance on July 21, 2014 of $75,000 to PVMI, a related party, as a partial payment for advances made by PVMI for escrow deposits used to secure properties for possible license acquisition in the San Diego market area.
	The closing dates on agreements Property 11 and 12 have been extended to 12/31/2014 and 01/15/2015, respectively subsequent to September 30, 2014.
	Other Commitments
	The Company has an obligation to a prior manufacturer of VII products to purchase certain unused components after a certain period of time. The amount the Company is now committed to purchase is approximately $56,000.

RESTATEMENT

RESTATEMENT	9 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]
RESTATEMENT	NOTE – 19 RESTATEMENT
	On December 30, 2014, Medbox, Inc. (the “Registrant”) filed with the Securities and Exchange Commission a Current Report on Form 8-K (the “Original 8-K”) disclosing its determination to (i) amend and restate its financial statements for the year ended December 31, 2013, the third and fourth quarters of 2013 and the first three quarters of 2014 and (ii) to examine the Company’s financial statements for the fiscal year 2012 and the first two quarters of 2013 and, if necessary, to restate those also. Thereafter, management, together with its professional advisor, undertook a comprehensive review of revenue recognition for all periods from 2012 to the present.
	Management and the outside professional advisor have completed the review of revenue recognition for the years 2012, 2013 and 2014. Conclusions that relate to the periods being restated herein include:
		1)	Revenue on some contracts with customers was recognized before all required criteria were met, resulting in an overstatement of revenue;
		2)	Certain transactions with related parties in the amount of $810,000 during the year ended December 31, 2013 were improperly recorded as revenue instead of capital contributions; and,
		3)	Certain inventory costs in 2013 were improperly capitalized resulting in an understatement of cost of sales. These are costs to seek licenses and locations that should have been recorded as expense prior to executing a contract with a customer, obtaining a license and closing on real estate to operate a dispensary or cultivation center.
	The combined impacts of all adjustments to the applicable line items in our consolidated financial statements for the periods covered by this Form 10-Q/A are provided in the tables below.
	Financial Statement Presentation. In addition to the restatement of our consolidated financial statements, we have also restated the following items to reflect certain changes noted above.
		•		Note 2 - Summary of Significant Accounting Policies
		•		Note 5 - Inventories
		•		Note 9 - Accounts and Notes Receivable
		•		Note 11 - Customer Deposits
		•		Note 16. - Related Parties
	MEDBOX, INC.
	CONSOLIDATED BALANCE SHEET
			September 30, 2014
			As originally			Impact of 2013			Early			Presentation			Restated
			presented			restatement			Recognition of			Reclass			(Unaudited)
			(Unaudited)						Revenue
	Assets
	Cash and cash equivalents		$	1,350,442											$	1,350,442
	Marketable securities			208,025												208,025
	Accounts receivable			337,475			(1,524,771	)		1,219,607						32,312
	Notes receivable			75,000												75,000
	Inventory			2,466,897			(636,468	)		(1,308,231	)					522,198
	Prepaid expenses and other current assets			1,012,195												1,012,195
	Total current assets			5,450,034												3,200,172
	Property and equipment			151,984												151,984
	Assets held for resale			399,594												399,594
	Investments, at cost			—												—
	Intangible assets			800,904												800,904
	Note receivable			155,000												155,000
	Goodwill			1,100,037												1,100,037
	Deposits and other assets			72,726												72,726
	Total assets		$	8,130,279			(2,161,239	)		(88,623	)		—		$	5,880,417
	Liabilities and Stockholders’ Equity
	Accounts payable and accrued expenses		$	1,505,998			(150,000	)		(34,000	)				$	1,321,998
	Deferred revenue						683,621			390,311						1,073,932
	Notes payable			299,605												299,605
	Related party notes payable			491,674												491,674
	Convertible notes payable			1,939,801												1,939,801
	Derivative liability			1,228,108												1,228,108
	Customer deposits			587,088			582,675			415,045						1,584,808
	Total current liabilities			6,052,274			1,116,296			771,356						7,939,926
	Stockholders’ Equity
	Preferred stock			3,000												3,000
	Common stock			30,105												30,105
	Additional paid-in capital			10,244,278			1,371,000									11,615,278
	Common stock subscribed			—												—
	Treasury stock			(1,209,600	)											(1,209,600	)
	Accumulated deficit			(6,989,778	)		(4,648,535	)		(859,979	)		158,507			(12,339,785	)
	Accumulated other comprehensive loss												(158,507	)		(158,507	)
	Total stockholders’ equity			2,078,005			(3,277,535	)		(859,979	)		—			(2,059,509	)
	Total liabilities and stockholders’ equity		$	8,130,279											$	5,880,417
	MEDBOX, INC.
	CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
			For Nine Months Ended September 30, 2014
			As originally			Early Recognition of			Restated
			presented			Revenue
	Revenue		$	836,427			(302,345	)	$	534,082
	Revenue from related party			1,000,000			(949,890	)		50,110
	Less: allowances and refunds			(1,229,710	)		1,169,710			(60,000	)
	Net revenue			606,717			(82,525	)		524,192
	Cost of revenues			2,183,874			1,308,231			3,492,105
Gross margin			(1,577,157	)		(1,390,756	)		(2,967,913	)
Operating expenses
Selling and marketing			749,212						749,212
Research and development			136,656						136,656
General and administrative			2,682,519			(530,777	)		2,151,742
Stock based compensation			1,031,640						1,031,640
Total operating expenses			4,600,027						4,069,250
Loss from operations			(6,177,184	)					(7,037,163	)
Other income (expense)
Interest income (expense), net			(314,078	)					(314,078	)
Change in fair value of derivative liabilities			548,315						548,315
Total other income			234,237						234,237
Loss before provision for income			(5,942,947	)					(6,802,926	)
taxes
Provision for income taxes			—						—
Net loss		$	(5,942,947	)		(859,979	)	$	(6,802,926	)
Earnings per share attributable to common stockholders
Basic		$	(0.20	)				$	(0.22	)
Diluted		$	(0.20	)				$	(0.22	)
Weighted average shares outstanding
Basic			30,472,447						30,472,447
Diluted			30,472,447						30,472,447
Other Comprehensive loss
Net loss								$	(6,802,926	)
Unrealized loss from marketable securities									(158,507	)
Comprehensive loss								$	(6,961,433	)
MEDBOX, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
		For Three Months Ended September 30, 2014
		As originally			Early Recognition			Restated
		presented			of Revenue
Revenue		$	107,429			65,647		$	173,076
Revenue from related party			—						—
Less: allowances and refunds			—						—
Net revenue			107,429			65,647			173,076
Cost of revenues			743,397			1,070,165			1,813,562
Gross margin			(635,968	)		(1,004,518	)		(1,640,486	)
Operating expenses
Selling and marketing			319,204						319,204
Research and development			61,623						61,623
General and administrative			1,363,440			(410,777	)		952,663
Stock based compensation			1,031,640						1,031,640
Total operating expenses			2,775,907						2,365,130
Loss from operations			(3,411,875	)					(4,005,616	)
Other expense
Interest income (expense), net			(339,231	)					(339,231	)
Change in fair value of derivative liabilities			548,315						548,315
Total other income			209,084						209,084
Loss before provision for income			(3,202,791	)					(3,796,532	)
taxes
Provision for income taxes			—						—
Net loss		$	(3,202,791	)		(593,741	)	$	(3,796,532	)
Earnings per share attributable to common stockholders
Basic		$	(0.11	)				$	(0.13	)
Diluted		$	(0.07	)				$	(0.13	)
Weighted average shares outstanding
Basic			30,371,299						30,371,299
Diluted			45,371,299						30,371,299
Other Comprehensive loss
Net loss								$	(3,796,532	)
Unrealized loss from marketable securities									(158,507	)
Comprehensive loss								$	(3,955,039	)
MEDBOX, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
		For Nine Months Ended September 30, 2013
		As originally			Early Recognition			Contributions			Restated
		presented			of Revenue			to capital
Revenue		$	4,801,062			(2,146,686	)		(810,000	)	$	1,844,376
Revenue from related party			—									—
Less: allowances and refunds			—									—
Net revenue			4,801,062									1,844,376
Cost of revenues			2,442,592			(184,465	)					2,258,127
Gross margin			2,358,470			(1,962,221	)		(810,000	)		(413,751	)
Operating expenses
Selling and marketing			506,393									506,393
Research and development			46,733									46,733
General and administrative			1,876,505									1,876,505
Stock based compensation			—									—
Total operating expenses			2,429,631									2,429,631
Loss from operations			(71,161	)								(2,843,382	)
Other income (expense)
Interest income (expense), net			(1,884	)								(1,884	)
Total other expense			(1,884	)								(1,884	)
Loss before provision for income			(73,045	)								(2,845,266	)
taxes
Provision for income taxes			(29,220	)								(29,220	)
Net loss		$	(43,825	)		(1,962,221	)		(810,000	)	$	(2,816,046	)
Earnings per share attributable to common stockholders
Basic		$	(0.00	)							$	(0.10	)
Diluted		$	(0.00	)							$	(0.10	)
Weighted average shares outstanding
Basic			28,658,556									28,658,556
Diluted			44,372,842									28,658,556
MEDBOX, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
		For Three Months Ended September 30, 2013
		As originally			Early Recognition			Restated
		presented			of Revenue
Revenue		$	1,980,720			(666,542	)	$	1,314,178
Revenue from related party			—						—
Less: allowances and refunds			—						—
Net revenue			1,980,720						1,314,178
Cost of revenues			1,641,495			165,535			1,807,030
Gross margin			339,225			(832,077	)		(492,852	)
Operating expenses
Selling and marketing			91,136						91,136
Research and development			28,233						28,233
General and administrative			522,372						522,372
Stock based compensation			—						—
Total operating expenses			641,741						641,741
Loss from operations			(302,516	)					(1,134,593	)
Other income (expense)
Interest income (expense), net			4,311						4,311
Change in fair value of derivative liabilities			—						—
Total other income			4,311						4,311
Loss before provision for income			(298,205	)					(1,130,282	)
taxes
Provision for income taxes			(119,280	)					(119,280	)
Net loss		$	(178,925	)		(832,077	)	$	(1,011,002	)
Earnings per share attributable to common stockholders
Basic		$	(0	)				$	(0	)
Diluted		$	(0	)				$	(0	)
Weighted average shares outstanding
Basic			29,298,284						29,298,284
Diluted			44,298,284						29,298,284

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 20– SUBSEQUENT EVENTS
	During the third quarter of 2014, the CEO of the Company and the Chairman of the Board, Mr. Guy Marsala received 20,000 shares from the founder and major shareholder of the Company out of his personal holdings to compensate for his superior performance. On October 24, 2014 the Compensation Committee of the Board of Directors recommended that shares be returned to the founder and issued by the Company as part of the yearly RSU grant. In November 2014, Mr. Marsala returned 20,000 shares to founder and major shareholder and 20,000 additional shares were approved to increase Mr. Marsala’s first year RSU grant from 50,000 RSU’s to 70,000 RSU’s.
	On October 17, 2014 the Company entered into an assignment agreement with its affiliate PVM International (PVMI) through which PVMI assigned all rights and titles for any opened escrow on real estate purchase agreements in San Diego in exchange for a related party notes payable from the Company. As of the signing date the agreement was valued at $190,400 which represented the value of escrow deposits paid by PVMI for eight different real estate agreements. Also on the date of the assignment agreement the Company paid $50,000 into an escrow account for PVMI. The escrow was related to one of the eight real estate purchase agreements that were part of the assignment.
	As of October 30, 2014 the Company was unsuccessful in obtaining the license associated with one of the locations. As a result the Company canceled one agreement with a purchase price of $3,500,000 and received the earnest money refund in the amount of $60,000 out of initially $100,000 paid; $40,000 represents a non-refundable fee according to the agreement that the escrow would release to seller $10,000 on the first day of each month following the signing and additional $10,000 with signing on July 21, 2014.
	On October 20, 2014 the Company received a $155,000 payment on the promissory note receivable from its Canadian partner plus accrued interest of $6,423.56. The full payment retired the note receivable.
	Effective November 1, 2014 the Company terminated two leases from unrelated third parties for offices located in West Hills, California and Scottsdale, Arizona with monthly lease payments of $1,300 and $1,420. The West Hills lease was on a month to month basis. The Arizona lease term expired on October 31, 2014.
	The Company utilized Dr. Bruce Consulting which is a related party and 100% owned by one of Company’s major shareholder and former Chief Executive Officer for management consulting and advisory service. The Company paid an additional $12,500 for consulting services in November 2014.
	On October 13, 2014, Mr. Vincent Mehdizadeh resigned as an officer of the Company. Mr. Mehdizadeh will continue to serve as a consultant to the Company. In his new role, Mr. Mehdizadeh will provide consulting services and will have the title of Founder and Senior Advisor. In connection therewith, on October 13, 2014, the Company entered into a consulting agreement with Mr. Mehdizadeh, pursuant to which the Company agreed to pay Mr. Mehdizadeh a monthly fee of $25,000 for consulting services to be performed by Mr. Mehdizadeh. The monthly consulting fee will be reduced to $12,500 per month if Mr. Mehdizadeh is engaged in trading any of the Company’s securities at any time within the preceding 30 day period. The consulting agreement has a two-year term, which term will automatically be extended for successive additional one-year terms, unless either party provides written notice to the other 90 days prior to the expiration of the initial term or any successive term, that Mr. Mehdizadeh’s agreement will not be extended.
	As of filing date the Company issued 337,186 shares of common stock to two board members from a total grant of 346,875 awarded by the Compensation Committee to board members.
	On October 16, 2014, Thomas Iwanski resigned as Chief Financial Officer, and C. Douglas (“Doug”) Mitchell was elected as Chief Financial Officer of the Company and Corporate Secretary.
	Mr. Iwanski agreed to serve as a consultant to the Company for a transition period. The Company agreed to pay Mr. Iwanski $10,000 for services provided during the month of October 2014 and $200 per hour for consulting services rendered after October 31, 2014. The Company also agreed to issue Mr. Iwanski 100,000 Restricted Stock Units (“RSU’s”) for his service to the Company.
	In connection with Mr. Mitchell’s election as Chief Financial Officer, on October 16, 2014, the Company entered into an employment agreement with Mr. Mitchell (the “Employment Agreement”). Pursuant to the Employment Agreement, the Company agreed to engage Mr. Mitchell, and Mr. Mitchell agreed to serve as the Company’s Chief Financial Officer, for a two-year term, which term will automatically be extended for successive additional one-year terms, unless either party provides written notice to the other 90 days prior to the expiration of the initial term or any successive term, that the Employment Agreement will not be renewed. The Company agreed to pay Mr. Mitchell a salary of $190,000 per year and to pay Mr. Mitchell $2,500 per month for living expenses in the West Hollywood, California area. Mr. Mitchell will also be entitled to an annual bonus of up to 35% of his salary, payable of up to 50% in cash and the balance payable in equity of the Company, subject to performance criteria and objectives to be established by mutual agreement of the CEO of the Company and Mr. Mitchell within 90 days of the effective date of the Employment Agreement, and thereafter from time to time by the CEO in consultation with Mr. Mitchell. Mr. Mitchell will also be entitled to an award of restricted stock units, to be issued within 90 days of the effective date of the Employment Agreement, under the Company’s Equity Incentive Plan, in the amount of 7,500 shares of common stock each calendar quarter Mr. Mitchell serves as Chief Financial Officer of the Company.
	The Company may terminate the Employment Agreement with or without Cause (as defined in the Employment Agreement) upon written notice to Mr. Mitchell. In the event the Company terminates the Employment Agreement without Cause, Mr. Mitchell terminates the Employment Agreement with Good Reason (as defined in the Employment Agreement), or the Employment Agreement is not renewed as a result of notice to Mr. Mitchell provided 90 days prior to expiration of the initial or a renewal term, Mr. Mitchell will be entitled to payment of one-half his annual salary. Termination by the Company within 365 days of a Change of Control (as defined in the Employment Agreement) in the absence of Cause will conclusively be deemed a termination by the Company without Cause.
	On October 22, 2014, Jennifer S. Love was elected to the board of directors of the Company. Ms. Love was also elected to serve as Chairperson of the Audit Committee.
	Ms. Love, 52, has been Senior Vice President and Chief Security Officer of Cablevision Services Corporation since August 2012. Previously, from 1987 to 2012, Ms. Love was with the Federal Bureau of Investigation, including as Assistant Director of the Security Division from July 2011 to June 2012. Ms. Love received a Bachelor of Science in Accounting from Jackson State University. Jennifer Love was granted 19,452 RSU’s for 2014. Her contract calls for grants of 100,000 RSU’s for each succeeding year of service beginning on April 1, 2015.
	On October 19, 2014, the Company received the sixth (last) warrant for 33,333 shares of common stock as a payment for services provided to MJ Holdings. The warrant was initially valuated at $13,033 using the Black Scholes model.
	On October 30, 2014, the Company appointed Tim Morrissey as V.P. and Director of Vaporfection International, Inc. Mr. Morrissey is the founder and Chief Executive Officer of Head Choice Inc., which is involved in many facets of the vaporization industry including consultation, manufacturing, sales and distribution.
	The Company plans to re-file an amendment to the Form S-1 it filed in connection with the July 2014 and September 2014 purchase agreements to include financial information from this Form 10-Q/A on or about November 14, 2014.
	The registration rights agreement entered into in connection with the July 2014 purchase agreement requires the Company to have a Form S-1 declared effective on or before November 18, 2014. As noted above, it is expected the amended Form S-1 will not be effective until December 4, 2014. As a result of the delay in effectiveness for the Form S-1, the conversion rate for the common stock to be issued as repayment of the debentures issued pursuant to the July 2014 purchase agreement will be, during the period commencing 120 days after the initial closing date until to the registration statement is effective, reduced to 63% of the volume weighted average price for 20 days prior to the issuance from 70% of the volume weighted average price originally stipulated in the loan agreements. This reduction in the conversion rate will increase our interest expense beginning in the fourth quarter of 2014.
	On November 10, 2014, the Los Angeles Regional Office of the Securities and Exchange Commission (the “SEC”) notified the Company that it is conducting an investigation pertaining to the Company and issued a subpoena to the Company for documents from December 1, 2011 to the present relating to the matters it is reviewing. The Company plans to cooperate fully with the SEC staff to complete the investigation on a timely basis.
	The SEC said it is trying to determine whether there have been any violations of the Federal Securities Laws. It said further that the fact of the investigation does not mean that it has concluded that the Company or anyone else has broken the law or that it has a negative opinion of any person, entity or security.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (RESTATED) (Policies)

9 Months Ended

Sep. 30, 2014

Accounting Policies [Abstract]

Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the accounts of Medbox, Inc. and its wholly owned subsidiaries. All intercompany transactions have been eliminated.

Use of Estimates

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the condensed consolidated financial statements as well as the reported expenses during the reporting periods. The Company’s significant estimates and assumptions include the valuation of the Company’s common stock used in the valuation of goodwill, accounts receivable and note receivable collectability, inventory, advances on investments, the valuation of restricted stock and warrants received from customers, the amortization and recoverability of capitalized patent costs and useful lives of long-lived assets the derivative liability, and income tax expense. Some of these judgments can be subjective and complex, and, consequently, actual results may differ from these estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from these estimates.

Concentrations of Credit Risk

Concentrations of Credit Risk (Restated)

The Company maintains cash balances at several financial institutions in the Los Angeles, California area and Florida. Accounts at each institution are insured by the Federal Deposit Insurance Corporation up to $250,000. At September 30, 2014 and December 31, 2013, the Company’s uninsured balances totaled $967,347 and $0, respectively. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible.

At September 30, 2014, one customer, represented 77.4% of outstanding receivables

September 30, 2014

January -

December 31, 2013

January -

September 2014

September 2013

Accounts

Revenue

Accounts

Revenue

Receivable

Receivable

Amount,

%

Amount,

%

Amount,

%

Amount,

%

$

$

$

$

A

—

—

190,131

32.5

%

150,000

44.2

%

325,000

17.6

%

B

—

—

175,000

30

%

115,200

33.9

%

C

25,000

77.4

%

—

—

D

E

25,000

77.4

%

365,131

62.5

%

265,200

78.1

%

325,000

17.6

%

Total

32,312

100

%

584,191

100

%

339,736

100

%

1,844,376

100

%

Advertising and Marketing Costs

Advertising and Marketing Costs

Advertising and marketing costs are expensed as incurred. The Company incurred advertising and marketing costs of $319,204 and $91,136 for the three months ended September 30, 2014 and 2013, and $749,212 and $506,393 for the nine months ended September 30, 2014 and 2013, respectively.

Research and Development

Research and Development

Research and development expenses are charged to operations as incurred. The Company incurred research and development costs of $61,623 and $28,233 for the three months ended September 30, 2014 and 2013, and $136,656 and $46,733 for the nine months ended September 30, 2014 and 2013, respectively.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Pursuant to ASC No. 825, Financial Instruments, the Company is required to estimate the fair value of all financial instruments included on its balance sheets. The carrying value of cash, accounts receivable, other receivables, inventory, accounts payable and accrued expenses and notes payable, related party notes payable, customer deposits, provision for customer refunds and short term loans payable approximate their fair value due to the short period to maturity of these instruments. The Company’s marketable securities and related customer deposits require fair value measurement on a recurring basis as the Company has received advance payment of restricted stock in a publicly traded company for contracted services and received warrants for service provided to unrelated third party. The Company has no exposure to gain or loss on the increase or decrease in the value of the marketable securities received as a payment from customer as any shortfall in the ultimate liquidated value of the securities will be supplemented by additional restricted stock from the customer and any liquidation in excess above the Company’s billings will be returned to the customer. The securities received as a payment for services provided will be exposed to gains or losses following their initial evaluation as of the date the revenue was earned.

Warrants and other financial assets received as a payment for the services provided are recorded as “Marketable securities” under the current assets if they are expected to be realized within 12 months. The Company uses the Black-Scholes model to measure the value of the warrants. At each reporting date the Company will reevaluate the value of marketable securities and record any changes in value to other comprehensive income (loss) under “Unrealized gain or losses from marketable securities”.

Embedded derivative - The Company’s convertible notes payable include embedded features that require bifurcation and are accounted for as a separate embedded derivative (see Note 13). The Company has estimated the fair market value of the embedded derivative of the Notes as the difference between the fair market value of the Notes with the conversion feature and the fair market value of the Notes without the conversion feature associated with the embedded derivative, in both cases using relevant market data. In the case of the fair market value of the Notes with the conversion feature, a binomial lattice model was used utilizing a discount rate based on variable conversion probability. In the case of the fair market value of the Notes without the conversion feature associated with the embedded derivative, a discounted cash flow approach was used. The key valuation assumptions used consist of the price of the Company’s stock, a risk free interest rate based on the average yield of a one year Treasury note and expected volatility of the Company’s common stock all as of the measurement dates. The Company considers these inputs Level 3 assumptions.

A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:

Level 1

Quoted prices in active markets for identical assets or liabilities.

Level 2

Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly.

Level 3

Significant unobservable inputs that cannot be corroborated by market data.

The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the liabilities that are measured at fair value on a recurring basis.

Total

Quoted Prices

Quoted Prices

Significant

in Active

for Similar

Unobservable

Markets for

Assets or

Inputs

Identical

Liabilities in

(Level 3)

Assets or

Active

Liabilities

Markets

(Level 1)

(Level 2)

September 30, 2014

Marketable securities

$

208,025

$

208,025

$

—

$

—

Conversion Feature

1,228,108

—

—

1,228,108

Total

$

1,436,133

$

208,025

$

—

$

1,228,108

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis:

For the nine months

ended

September 30, 2014

Total

Beginning balance

$

—

Initial recognition of conversion feature

1,776,423

Change in fair value of conversion feature

(548,315

)

Ending balance

$

1,228,108

Revenue Recognition (Restated)

Revenue Recognition (Restated)

The Company applies the revenue recognition provisions pursuant to ASC No. 605, Revenue Recognition, which provides guidance on the recognition, presentation and disclosure of revenue in financial statements filed with the SEC. The guidance outlines the basic criteria that must be met to recognize the revenue and provides guidance for disclosure related to revenue recognition policies.

Revenue is only recognized when the following four criteria are met: 1) persuasive evidence of an arrangement exists, 2) delivery has occurred or services have been rendered, 3) sales price is fixed and determinable and 4) collectability is reasonably assured. For multi-year contracts with upfront payments made by customers, the upfront payments are recognized over the longer of the contract period or the customer relationship. For contracts that include multiple deliverables such as the build out of customer facilities, the Company recognizes revenue when a milestone is reached in the contract such as securing the location, delivery of dispensing machines or completion of the facility. The contract terms are broken down in specific milestones with specific attributable revenue to be earned upon successful completion of the milestone terms. ( e.g.. if a milestone is completing construction on a client dispensary, the condition for the revenue to be recorded is after issuance of a certificate of occupancy for the newly completed facility. The Company will record a specified amount of revenue attributable to this milestone based on the contract). Equipment sales not associated with a consulting contract are recognized as the product is shipped and title passes. Advance payments from clients in advance of work performed are recorded as customer deposits on the balance sheet.

An allowance for bad debt is established for any customer when their balance is deemed as possibly uncollectible.

Provisions for estimated returns and allowances, and other adjustments are usually provided in the same period the related sales are recorded. The Company will at times allow customers to receive full refunds should regulatory events prevent the customer from being able to operate his contracted location. The provision for returns as well as an allowance for doubtful accounts is included in the Company’s balance sheet as determined by management.

Provisions for estimated returns and allowances, and other adjustments are provided in the same period the related sales are recorded. The Company will at times allow customers to get full refunds should political events prevent the customer from being able to operate his or her contracted location. The provision for returns as well as an allowance for bad debts will be included in the Company’s balance sheet should the Company deem such allowances justified.

Cost of Revenues (Restated)

Cost of Revenues (Restated)

Cost of revenue consists primarily of expenses associated with the delivery and distribution of our products and services. These include expenses related to the manufacture of our dispensary units, construction expense related to the customer dispensary, site selection and establishment of licensing requirements, and consulting expense for the continued management of the dispensary unit build out, server and security equipment, rent expense, energy and bandwidth costs, and support and maintenance costs prior to when the client moves in. We only begin capitalizing costs when we have obtained a license and a site for operation of a customer dispensary or cultivation center. The previously capitalized costs are charged to cost of revenue in the same period that the associated revenue is earned. In the case where it is determined that previously inventoried costs are in excess of the projected net realizable value of the sale of the licenses then the excess cost above net realizable value is written off to cost of revenues. In addition, cost of revenue related to our vaporizer line of products consists of direct procurement cost of the products along with costs associated with order fulfillment, shipping, inventory storage and inventory management costs.

Basic and Fully Diluted Net Income/Loss Per Share

Basic and Fully Diluted Net Income/Loss Per Share

Basic net income/loss per share is computed by dividing net income/loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net incomes per share include the effects of any outstanding options, warrants and other potentially dilutive securities. The Company did not consider any potentially dilutive common shares in the computation of diluted loss per share for the periods ending September 30, 2014 and December 31, 2013, due to the net loss, as they would have an anti-dilutive effect on EPS.

As of September 30, 2014 and December 31, 2013, the Company had 3,000,000 shares of Series A preferred stock outstanding with par value of $0.001 that could be converted into 15,000,000 shares of the Company’s common stock. The Company also had 295,854 warrants to purchase common stock outstanding as of September 30, 2014.

Accounts Receivable and Allowance for Bad Debts (Restated)

Accounts Receivable and Allowance for Bad Debts (Restated)

The Company is subject to credit risk as it extends credit to our customers for work performed as specified in individual contracts. The Company extends credit to its customers, mostly on an unsecured basis after performing certain credit analysis. Our typical terms require the customer to pay a portion of the contract price up front and the rest upon certain agreed milestones. The Company’s management periodically reviews the creditworthiness of its customers and provides for probable uncollectible amounts through a charge to operations and a credit to an allowance for doubtful accounts based on our assessment of the current status of individual accounts. Accounts still outstanding after the Company has used reasonable collection efforts are written off through a charge to the allowance for doubtful accounts. As of September 30, 2014 and December 31, 2013, the Company’s management considered all accounts outstanding fully collectible.

Property and Equipment

Property and Equipment

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses accelerated depreciation methods for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows:

Vehicles

5 years

Furniture and Fixtures

5 years

Office equipment

3 years

Assets Held for Resale

Assets Held for Resale

During 2014, the Company has entered into various real estate purchase agreements to support the filing of retail dispensary or cultivation facility licenses in certain states and localities. The cost of the acquired real estate is included in Assets Held for Resale on the balance sheet. The Company intends to sell the real estate to a long term investor after the license is granted. Accordingly, the company does not depreciate assets held for resale.

Income Taxes

Income Taxes

The Company accounts for income taxes under the asset and liability method in accordance with ASC 740. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities are classified as current and non-current based on their characteristics. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

In addition, the Company’s management performs an evaluation of all uncertain income tax positions taken or expected to be taken in the course of preparing the Company’s income tax returns to determine whether the income tax positions meet a “more likely than not” standard of being sustained under examination by the applicable taxing authorizes. This evaluation is required to be performed for all open tax years, as defined by the various statutes of limitations, for federal and state purposes.

Commitments and Contingencies

Commitments and Contingencies

Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

There were various accounting updates recently issued which are not expected to a have a material impact on the Company’s consolidated financial position, consolidated results of operations or cash flows.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (RESTATED) (Tables)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]
Schedules of Concentration of Risk, by Risk Factor	At September 30, 2014, one customer, represented 77.4% of outstanding receivables
		September 30, 2014						January -					December 31, 2013					January -
								September 2014										September 2013
		Accounts						Revenue					Accounts					Revenue
		Receivable											Receivable
		Amount,			%			Amount,		%			Amount,		%			Amount,		%
		$						$					$					$
	A		—			—			190,131		32.5	%		150,000		44.2	%		325,000		17.6	%
	B		—			—			175,000		30	%		115,200		33.9	%
	C		25,000			77.4	%		—		—
	D
	E
			25,000			77.4	%		365,131		62.5	%		265,200		78.1	%		325,000		17.6	%
	Total		32,312			100	%		584,191		100	%		339,736		100	%		1,844,376		100	%
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the liabilities that are measured at fair value on a recurring basis.
		Total			Quoted Prices			Quoted Prices		Significant
					in Active			for Similar		Unobservable
					Markets for			Assets or		Inputs
					Identical			Liabilities in		(Level 3)
					Assets or			Active
					Liabilities			Markets
					(Level 1)			(Level 2)
	September 30, 2014
	Marketable securities	$	208,025		$	208,025		$	—	$	—
	Conversion Feature		1,228,108			—			—		1,228,108
	Total	$	1,436,133		$	208,025		$	—	$	1,228,108
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis:
		For the nine months
		ended
		September 30, 2014
		Total
	Beginning balance	$	—
	Initial recognition of conversion feature		1,776,423
	Change in fair value of conversion feature		(548,315	)
	Ending balance	$	1,228,108

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2014
Estimated Useful Lives [Member]
Property, Plant and Equipment	The estimated useful lives for significant property and equipment categories are as follows:
	Vehicles	5 years
	Furniture and Fixtures	5 years
	Office equipment	3 years
Property And Equipment [Member]
Property, Plant and Equipment	Property and equipment at September 30, 2014 and December 31, 2013 consists of:
	Property and Equipment	September 30, 2014			December 31, 2013
	Office equipment	$	22,934		$	17,192
	Furniture and fixtures		74,404			73,567
	Website development		46,922			46,922
	Product tooling		50,503			24,100
			194,763			161,781
	Less accumulated depreciation		(42,779	)		(21,123	)
	Property and equipment, net	$	151,984		$	140,658

ACQUISITION_Tables

ACQUISITION (Tables)	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The total value of the acquisition was approximately $1,635,000 and has been allocated in accordance with ASC 805 as per the Company’s independent valuation as follows:
	Machinery & Equipment	$	70,000
	IP and related technology		287,000
	Amortizable intangible assets:
	Customer contracts and related relationships		314,000
	Trade name, trademark, and domain name		46,000
	Non-compete covenants		23,000
	Goodwill		895,000
	Total assets acquired		1,635,000
	Fair value of liabilities assumed		(469,000	)
	Net fair value	$	1,166,000

INVENTORIES_Restated_Tables

INVENTORIES (Restated) (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	The consolidated inventories at September 30, 2014 and December 31, 2013 consist of the following:
		September 30, 2014		December 31, 2013
		(Restated)
	Work in process and related capitalized costs	$	—	$	242,488
	Deposits on dispensing machines		336,583		138,423
	Vaporizers and accessories		164,030		193,575
	Dispensing machines		21,585		58,500
	Total inventory, net	$	522,198	$	632,986

ASSETS_HELD_FOR_RESALE_Tables

ASSETS HELD FOR RESALE (Tables)	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]
Disclosure of Long Lived Assets Held-for-sale	In the event of a default, as defined, the interest rate increases to 18% and the note can be accelerated.
	Assets held for resale	September 30, 2014		December 31, 2013
	Buildings held for resale	$	399,594	$	—
	Assets held for resale	$	399,594	$	—

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2014
Estimated Useful Lives [Member]
Schedule of Finite-Lived Intangible Assets	The estimated useful lives for significant intangible assets are as follows:
	Distributor Relationship	10 years
	Domain Names	10 years
	IP/Technology/Patents	10 years
	Non-Compete covenants	3 years
Finite-Lived Intangible Assets [Member]
Schedule of Finite-Lived Intangible Assets
	Intangible assets	September 30, 2014			December 31, 2013
	Distributor relationship	$	314,000		$	314,000
	IP/technology/patents		403,363			332,179
	Domain names		131,000			46,000
	Non-compete covenants		23,000			23,000
	Subtotal		871,363			715,179
	Less accumulated amortization		(70,459	)		(32,750	)
	Intangible assets, net	$	800,904		$	682,429

MARKETABLE_SECURITIES_Tables

MARKETABLE SECURITIES (Tables)	9 Months Ended
	Sep. 30, 2014
Marketable Securities	Marketable securities of the Company represent the shares received as a payment from clients for services provided.
	Marketable securities	Value as of		Value as of
		September 30, 2014		December 30, 2013
	Shares received as a payment from client	$	176,400	$	184,800
	Securities from MJ Holdings, Inc.		31,625		—
	Total marketable securities	$	208,025	$	184,800
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	The following data were introduced in the model in order to assess the value of the warrants assuming that the Company expects to keep the warrants for six months:
	Black-Scholes Calculator Data	Initial Valuation and Recognition
		#1		#2			#3			#4		#5
	Warrant
	Stock price, $		8.69		4			8			6.15		2.01
	Exercise price, $		6.41503521		8.454933			7.874619			6.953694		3.53412
	Time to maturity, Years		0.5		0.5			0.5			0.5		1
	Annual risk-free rate, %		0.05		0.05			0.05			0.05		0.04
	Annualized volatility, %		70		70			70			70		70
	Black-Scholes Value per warrant, $		2.876		0.08			1.616			0.918		0.214
	Number of warrants/shares		33,333		33,333			33,333			33,333		33,333
	Total value of warrants/shares, $		95,866		2,666			53,867			30,600		7,133
	Fair Value of Warrants	As of September 30, 2014
		#2		#3			#4			#5
	Warrant
	Stock price, $		2.01		2.01			2.01			2.01
	Exercise price, $		8.454933		7.874619			6.953694			3.53412
	Time to maturity, Years		1		1			1			1
	Annual risk-free rate, %		0.13		0.13			0.13			0.13
	Annualized volatility, %		70		70			70			70
	Black-Scholes Value per warrant, $		0.019		0.025			0.038			0.214
	Number of warrants/shares		33,333		33,333			33,333			33,333
	Total value of warrants/shares, $		633		834			1,267			7,133
Warrant [Member]
Marketable Securities	The following table represents the initial recognition value and subsequent adjustment as of reporting date:
	Warrants	Initial Fair		Fair Value at			Gain or (Loss)			Fair Value as of
		Value		Conversion						September 30,
										2014
	Warrant #1	$	95,866	$	(94,719	)	$	(1,147	)	$	—
	Conversion of the Warrant #1 to 10,825 shares		—		94,719			(72,961	)		21,758
	Warrant #2		2,666					(2,033	)		633
	Warrant #3		53,867					(53,033	)		834
	Warrant #4		30,600					(29,333	)		1,267
	Warrant #5		7,133					—			7,133
	Total	$	190,132	$	—		$	(158,507	)	$	31,625

CUSTOMER_DEPOSITS_RESTATED_Tab

CUSTOMER DEPOSITS (RESTATED) (Tables)	9 Months Ended
	Sep. 30, 2014
Banking and Thrift [Abstract]
Customer Advances And Deposits, Current	Advance payments from customers are recorded as customer deposits on the balance sheet.
	Customer deposits	September 30, 2014		December 31, 2013
		(Restated)
	Advance payments from customers	$	1,509,770	$	710,225
	Advance payments for vaporizers		75,038		75,636
	Total customer deposits	$	1,584,808	$	785,861

SHORTTERM_DEBT_Tables

SHORT-TERM DEBT (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]
Schedule of Short-term Debt	Short-term debt as of September 30, 2014 and December 31, 2013 consisted of:
	Short-term debt	September 30, 2014		December 31, 2013
	Notes payable to unrelated third party	$	299,605	$	75,000
	Notes payable to related party		491,674		111,794
	Total short-term debt	$	791,279	$	186,794

PREPAID_EXPENSES_AND_OTHER_CUR1

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	9 Months Ended
	Sep. 30, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure	Prepaid expenses and other currents assets as of September 30, 2014 and December 31, 2013 consisted of:
	Prepaid expenses and other current assets	September 30,		December 31,
		2014		2013
	Prepaid expenses
	Deferred loan cost	$	196,250	$	—
	Rent		5,262		3,962
	Directors & officers insurance		77,645		—
	Professional fees		30,000		52,739
	Other vendors		68,750		32,540
	Other current assets
	Earnest money deposits, net		634,288		—
	Prepaid expenses and other current assets	$	1,012,195	$	89,241

RESTRICTED_STOCK_AND_RESTRICTE1

RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	A summary of the activity related to restricted stock and RSUs for the nine months ended September 30, 2014 is presented below:
	Restricted stock	Total shares			Grant date fair
					value
	Restricted stock non-vested at January 1, 2014		—		$	—
	Restricted stock granted		346,875			10.4
	Restricted stock vested		(178,125	)		10.4
	Restricted stock forfeited		—			—
	Restricted stock non-vested at September 30, 2014		168,750		$	10.4
	Restricted stock units (RSU’s)	Total shares			Grant date fair
					value
	Restricted stock non-vested at January 1, 2014		—		$	—
	Restricted stock granted		171,875			10.4
	Restricted stock vested		(115,625	)		10.4
	Restricted stock forfeited					—
	Restricted stock non-vested at September 30, 2014		56,250		$	10.4
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	A summary of the expense related to restricted stock and RSUs for the three and nine months ended September 30, 2014 is presented below:
	Summary of the expense related to Restricted Stock and RSUs	Three months			Nine
		ended			months ended
		September 30,			September 30,
		2014			2014
	Restricted Stock	$	663,262		$	663,262
	RSU’s		368,378			368,378
	Total stock based compensation expense	$	1,031,640		$	1,031,640

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	The following table is a summary of our material contractual lease commitments as of September 30, 2014:
	Year Ending	Office Rent		Retail/Cultivation
				Facility Lease
	2014	$	44,484	$	22,200
	2015		177,936		88,800
	2016		177,936		88,800
	2017		88,968		88,800
	2018		—		88,800
	2019		—		29,600
	Total	$	489,324	$	407,000
Schedule of Real Estate Properties	A summary of open real estate purchase transactions as of September 30, 2014 is represented in the table below:
	Property	Purchase price		Closing		Net escrow balance		Date		Additional
				date				escrow opened		rents/fees paid to
										extend closing
										date
	1	$	3,500,000		12/11/14	$	60,000		7/25/14	$	—
	2		3,650,000		1/5/15		35,000		7/21/14		—
	3		2,450,000		12/1/14		80,000		8/13/14		—
	4		790,000		1/1/15		24,288		8/12/14		—
	5		480,000		1/31/15		16,000		8/12/14		—
	6		2,100,000		2/10/15		90,000		8/13/14		—
	7		595,000		1/31/15		10,000		8/13/14		—
	8		3,250,000		2/10/15		90,000		8/19/14		—
	9		2,400,000		2/8/15		19,000		8/19/14		—
	10		2,300,000		1/8/15		80,000		8/19/14		—
	11		695,000		10/18/14		10,000		6/28/14		—
	12		820,000		10/18/14		45,000		6/28/14		7,893
	13		—				75,000		7/21/14		—
	Total	$	23,030,000			$	634,288			$	7,893

RESTATEMENT_Tables

RESTATEMENT (Tables)	9 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]
Schedule of Prior Period Adjustments	The combined impacts of all adjustments to the applicable line items in our consolidated financial statements for the periods covered by this Form 10-Q/A are provided in the tables below.
	Financial Statement Presentation. In addition to the restatement of our consolidated financial statements, we have also restated the following items to reflect certain changes noted above.
		•		Note 2 - Summary of Significant Accounting Policies
		•		Note 5 - Inventories
		•		Note 9 - Accounts and Notes Receivable
		•		Note 11 - Customer Deposits
		•		Note 16. - Related Parties
	MEDBOX, INC.
	CONSOLIDATED BALANCE SHEET
			September 30, 2014
			As originally			Impact of 2013			Early			Presentation			Restated
			presented			restatement			Recognition of			Reclass			(Unaudited)
			(Unaudited)						Revenue
	Assets
	Cash and cash equivalents		$	1,350,442											$	1,350,442
	Marketable securities			208,025												208,025
	Accounts receivable			337,475			(1,524,771	)		1,219,607						32,312
	Notes receivable			75,000												75,000
	Inventory			2,466,897			(636,468	)		(1,308,231	)					522,198
	Prepaid expenses and other current assets			1,012,195												1,012,195
	Total current assets			5,450,034												3,200,172
	Property and equipment			151,984												151,984
	Assets held for resale			399,594												399,594
	Investments, at cost			—												—
	Intangible assets			800,904												800,904
	Note receivable			155,000												155,000
	Goodwill			1,100,037												1,100,037
	Deposits and other assets			72,726												72,726
	Total assets		$	8,130,279			(2,161,239	)		(88,623	)		—		$	5,880,417
	Liabilities and Stockholders’ Equity
	Accounts payable and accrued expenses		$	1,505,998			(150,000	)		(34,000	)				$	1,321,998
	Deferred revenue						683,621			390,311						1,073,932
	Notes payable			299,605												299,605
	Related party notes payable			491,674												491,674
	Convertible notes payable			1,939,801												1,939,801
	Derivative liability			1,228,108												1,228,108
	Customer deposits			587,088			582,675			415,045						1,584,808
	Total current liabilities			6,052,274			1,116,296			771,356						7,939,926
	Stockholders’ Equity
	Preferred stock			3,000												3,000
	Common stock			30,105												30,105
	Additional paid-in capital			10,244,278			1,371,000									11,615,278
	Common stock subscribed			—												—
	Treasury stock			(1,209,600	)											(1,209,600	)
	Accumulated deficit			(6,989,778	)		(4,648,535	)		(859,979	)		158,507			(12,339,785	)
	Accumulated other comprehensive loss												(158,507	)		(158,507	)
	Total stockholders’ equity			2,078,005			(3,277,535	)		(859,979	)		—			(2,059,509	)
	Total liabilities and stockholders’ equity		$	8,130,279											$	5,880,417
	MEDBOX, INC.
	CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
			For Nine Months Ended September 30, 2014
			As originally			Early Recognition of			Restated
			presented			Revenue
	Revenue		$	836,427			(302,345	)	$	534,082
	Revenue from related party			1,000,000			(949,890	)		50,110
	Less: allowances and refunds			(1,229,710	)		1,169,710			(60,000	)
	Net revenue			606,717			(82,525	)		524,192
	Cost of revenues			2,183,874			1,308,231			3,492,105
	Gross margin			(1,577,157	)		(1,390,756	)		(2,967,913	)
	Operating expenses
	Selling and marketing			749,212						749,212
	Research and development			136,656						136,656
	General and administrative			2,682,519			(530,777	)		2,151,742
	Stock based compensation			1,031,640						1,031,640
Total operating expenses			4,600,027						4,069,250
Loss from operations			(6,177,184	)					(7,037,163	)
Other income (expense)
Interest income (expense), net			(314,078	)					(314,078	)
Change in fair value of derivative liabilities			548,315						548,315
Total other income			234,237						234,237
Loss before provision for income			(5,942,947	)					(6,802,926	)
taxes
Provision for income taxes			—						—
Net loss		$	(5,942,947	)		(859,979	)	$	(6,802,926	)
Earnings per share attributable to common stockholders
Basic		$	(0.20	)				$	(0.22	)
Diluted		$	(0.20	)				$	(0.22	)
Weighted average shares outstanding
Basic			30,472,447						30,472,447
Diluted			30,472,447						30,472,447
Other Comprehensive loss
Net loss								$	(6,802,926	)
Unrealized loss from marketable securities									(158,507	)
Comprehensive loss								$	(6,961,433	)
MEDBOX, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
		For Three Months Ended September 30, 2014
		As originally			Early Recognition			Restated
		presented			of Revenue
Revenue		$	107,429			65,647		$	173,076
Revenue from related party			—						—
Less: allowances and refunds			—						—
Net revenue			107,429			65,647			173,076
Cost of revenues			743,397			1,070,165			1,813,562
Gross margin			(635,968	)		(1,004,518	)		(1,640,486	)
Operating expenses
Selling and marketing			319,204						319,204
Research and development			61,623						61,623
General and administrative			1,363,440			(410,777	)		952,663
Stock based compensation			1,031,640						1,031,640
Total operating expenses			2,775,907						2,365,130
Loss from operations			(3,411,875	)					(4,005,616	)
Other expense
Interest income (expense), net			(339,231	)					(339,231	)
Change in fair value of derivative liabilities			548,315						548,315
Total other income			209,084						209,084
Loss before provision for income			(3,202,791	)					(3,796,532	)
taxes
Provision for income taxes			—						—
Net loss		$	(3,202,791	)		(593,741	)	$	(3,796,532	)
Earnings per share attributable to common stockholders
Basic		$	(0.11	)				$	(0.13	)
Diluted		$	(0.07	)				$	(0.13	)
Weighted average shares outstanding
Basic			30,371,299						30,371,299
Diluted			45,371,299						30,371,299
Other Comprehensive loss
Net loss								$	(3,796,532	)
Unrealized loss from marketable securities									(158,507	)
Comprehensive loss								$	(3,955,039	)
MEDBOX, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
		For Nine Months Ended September 30, 2013
		As originally			Early Recognition			Contributions			Restated
		presented			of Revenue			to capital
Revenue		$	4,801,062			(2,146,686	)		(810,000	)	$	1,844,376
Revenue from related party			—									—
Less: allowances and refunds			—									—
Net revenue			4,801,062									1,844,376
Cost of revenues			2,442,592			(184,465	)					2,258,127
Gross margin			2,358,470			(1,962,221	)		(810,000	)		(413,751	)
Operating expenses
Selling and marketing			506,393									506,393
Research and development			46,733									46,733
General and administrative			1,876,505									1,876,505
Stock based compensation			—									—
Total operating expenses			2,429,631									2,429,631
Loss from operations			(71,161	)								(2,843,382	)
Other income (expense)
Interest income (expense), net			(1,884	)								(1,884	)
Total other expense			(1,884	)								(1,884	)
Loss before provision for income			(73,045	)								(2,845,266	)
taxes
Provision for income taxes			(29,220	)								(29,220	)
Net loss		$	(43,825	)		(1,962,221	)		(810,000	)	$	(2,816,046	)
Earnings per share attributable to common stockholders
Basic		$	(0.00	)							$	(0.10	)
Diluted		$	(0.00	)							$	(0.10	)
Weighted average shares outstanding
Basic			28,658,556									28,658,556
Diluted			44,372,842									28,658,556
MEDBOX, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
		For Three Months Ended September 30, 2013
		As originally			Early Recognition			Restated
		presented			of Revenue
Revenue		$	1,980,720			(666,542	)	$	1,314,178
Revenue from related party			—						—
Less: allowances and refunds			—						—
Net revenue			1,980,720						1,314,178
Cost of revenues			1,641,495			165,535			1,807,030
Gross margin			339,225			(832,077	)		(492,852	)
Operating expenses
Selling and marketing			91,136						91,136
Research and development			28,233						28,233
General and administrative			522,372						522,372
Stock based compensation			—						—
Total operating expenses			641,741						641,741
Loss from operations			(302,516	)					(1,134,593	)
Other income (expense)
Interest income (expense), net			4,311						4,311
Change in fair value of derivative liabilities			—						—
Total other income			4,311						4,311
Loss before provision for income			(298,205	)					(1,130,282	)
taxes
Provision for income taxes			(119,280	)					(119,280	)
Net loss		$	(178,925	)		(832,077	)	$	(1,011,002	)
Earnings per share attributable to common stockholders
Basic		$	(0	)				$	(0	)
Diluted		$	(0	)				$	(0	)
Weighted average shares outstanding
Basic			29,298,284						29,298,284
Diluted			44,298,284						29,298,284

NOTE_1_BUSINESS_ORGANIZATION_N

NOTE 1 - BUSINESS ORGANIZATION, NATURE OF OPERATIONS (Detail) (Vaporfection International Inc. [Member])	9 Months Ended
	Sep. 30, 2014
Vaporfection International Inc. [Member]
NOTE 1 - BUSINESS ORGANIZATION, NATURE OF OPERATIONS (Details) [Line Items]
Number of Subsidiaries	8

NOTE_2_SUMMARY_OF_SIGNIFICANT_

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Cash, FDIC Insured Amount	$250,000		$250,000
Cash, Uninsured Amount	967,347		967,347		0
Advertising Expense	319,204	91,136	749,212	506,393
Research and Development Expense	$61,623	$28,233	$136,656	$46,733
Warrants to purchase common stock outstanding	295,854		295,854
Series A Preferred Stock [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Preferred Stock, Shares Outstanding (in Shares)	3,000,000		3,000,000		3,000,000
Preferred Stock, No Par Value (in Dollars per share)	$0.00		$0.00		$0.00
Convertible Preferred Stock, Shares Issued upon Conversion (in Shares)	15,000,000		15,000,000		15,000,000

NOTE_2_SUMMARY_OF_SIGNIFICANT_1

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedules of Concentration of Risk, by Risk Factor (Detail) (USD $)	9 Months Ended	12 Months Ended	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013
Accounts Receivable [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Accounts Receivable Amount	$32,312	$339,736
Concentration Risk, Percentage	100.00%	100.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Gross Revenue Generated	584,191		1,844,376
Concentration Risk, Percentage	100.00%		100.00%
Customer A [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Accounts Receivable Amount	0	150,000
Concentration Risk, Percentage	0.00%	44.20%
Customer A [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Gross Revenue Generated	190,131		325,000
Concentration Risk, Percentage	32.50%		17.60%
Customer B [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Accounts Receivable Amount	0	115,200
Concentration Risk, Percentage	0.00%	33.90%
Customer B [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Gross Revenue Generated	175,000
Concentration Risk, Percentage	30.00%
Customer C [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Accounts Receivable Amount	25,000
Concentration Risk, Percentage	77.40%
Customer C [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Gross Revenue Generated	0
Concentration Risk, Percentage	0.00%
Customer A & B [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Accounts Receivable Amount		265,200
Concentration Risk, Percentage		78.10%
Customer A & B [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Gross Revenue Generated	365,131		325,000
Concentration Risk, Percentage	62.50%		17.60%
Subtotal [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Concentration Risk [Line Items]
Accounts Receivable Amount	$25,000
Concentration Risk, Percentage	77.40%

NOTE_2_SUMMARY_OF_SIGNIFICANT_2

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 30, 2013
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Marketable securities	$208,025	$184,800	$184,800
Conversion Feature	1,228,108	0
Total	1,436,133
Fair Value, Inputs, Level 1 [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Marketable securities	208,025
Conversion Feature	0
Total	208,025
Fair Value, Inputs, Level 2 [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Marketable securities	0
Conversion Feature	0
Total	0
Fair Value, Inputs, Level 3 [Member]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Marketable securities	0
Conversion Feature	1,228,108
Total	$1,228,108

NOTE_2_SUMMARY_OF_SIGNIFICANT_3

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Abstract]
Beginning balance	$0
Initial recognition of conversion feature	1,776,423
Change in fair value of conversion feature	-548,315
Ending balance	$1,228,108

NOTE_2_SUMMARY_OF_SIGNIFICANT_4

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Property, Plant and Equipment, Estimated Useful Lives (Detail)	9 Months Ended
	Sep. 30, 2014
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years

NOTE_3_ACQUISITION_Detail

NOTE 3 - ACQUISITION (Detail) (USD $)	0 Months Ended	3 Months Ended		12 Months Ended
	Mar. 22, 2013	Sep. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Mar. 22, 2013
NOTE 3 - ACQUISITION (Details) [Line Items]
Goodwill		$1,100,037		$1,090,037
Vaporfection International Inc. [Member]
NOTE 3 - ACQUISITION (Details) [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%				100.00%
Business Acquisition, Equity Interest Issued or Issuable, Description	The Company issued 260,854 warrants to shareholders of VII allowing them to purchase one (1) share of Medbox common stock at $.001 per share beginning April 1, 2014.
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)	260,854
Fair Value Assumptions, Exercise Price (in Dollars per share)	$4.47				$4.47
Business Combination, Consideration Transferred, Liabilities Incurred	470,000
Business Combination, Consideration Transferred	1,635,000
Finite-Lived Intangible Asset, Useful Life	10 years
Goodwill	895,000				895,000
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities			10,000	195,000
Goodwill, Period Increase (Decrease)		$205,000
Business Combination, Contingent Consideration Arrangements, Description	In addition to the above warrants, the purchase agreement and associated consulting contract with the prior management company of the business unit calls for additional shares of common stock to be issued in the event that the performance of the business unit exceeds $11,818,140 of accumulated EBITBA over the subsequent 4 year operating period.
Settlement With Former Shareholders [Member] | Vaporfection International Inc. [Member]
NOTE 3 - ACQUISITION (Details) [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)	130,427

NOTE_3_ACQUISITION_Schedule_of

NOTE 3 - ACQUISITION - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Mar. 22, 2013
NOTE 3 - ACQUISITION (Details) - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Goodwill	$1,100,037	$1,090,037
Vaporfection International Inc. [Member]
NOTE 3 - ACQUISITION (Details) - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Machinery & Equipment			70,000
Goodwill			895,000
Total assets acquired			1,635,000
Fair value of liabilities assumed			-469,000
Net fair value			1,166,000
Customer Relationships [Member] | Vaporfection International Inc. [Member]
NOTE 3 - ACQUISITION (Details) - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Intangible assets			314,000
Trademarks and Trade Names [Member] | Vaporfection International Inc. [Member]
NOTE 3 - ACQUISITION (Details) - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Intangible assets			46,000
Noncompete Agreements [Member] | Vaporfection International Inc. [Member]
NOTE 3 - ACQUISITION (Details) - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Intangible assets			23,000
IP and Related Technology [Member] | Vaporfection International Inc. [Member]
NOTE 3 - ACQUISITION (Details) - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Line Items]
Intangible assets			$287,000

NOTE_4_INVESTMENTS_Detail

NOTE 4 - INVESTMENTS (Detail) (USD $)	0 Months Ended
	Feb. 27, 2014	Feb. 08, 2013	Mar. 12, 2013	Jun. 05, 2014	Sep. 30, 2014	Dec. 31, 2013
NOTE 4 - INVESTMENTS (Details) [Line Items]
Investment Owned, at Cost					$0	$1,200,000
Treasury Stock, Value					1,209,600	0
Treasury Stock, Shares (in Shares)					60,000
Bio-Tech Medical Software [Member]
NOTE 4 - INVESTMENTS (Details) [Line Items]
Equity Method Investment, Additional Information		The Company advanced $600,000 upon execution of this agreement for the right to purchase with the remaining balance of $900,000 due and payable in installments at various dates by August 25, 2013. On June 26, 2013, the Company notified Bio-Tech that it was canceling the agreement.
Payments to Acquire Trading Securities Held-for-investment		600,000
Licensing Agreement, Term	5 years
Bio-Tech Medical Software [Member] | Maximum [Member]
NOTE 4 - INVESTMENTS (Details) [Line Items]
Investment, Authorized Shares Available for Purchase (in Shares)		833,333
Equity Method Investment, Ownership Percentage		25.00%
Investment, Purchase Price		1,500,000
MedVend Holdings LLC [Member]
NOTE 4 - INVESTMENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage			50.00%
Equity Method Investment, Additional Information			In May 2013, the three members of MedVend were named in a lawsuit by that entity's minority shareholders alleging improper conveyance of the three members' ownership interest in MedVend to the Company. Accordingly, also in May 2013, Medbox filed suit against MedVend and the three members of that entity that were involved in the transaction.
Investment Owned, at Cost			4,100,000
MedVend Holdings LLC [Member] | Amount Paid Upon Execution of the Contract [Member]
NOTE 4 - INVESTMENTS (Details) [Line Items]
Payments to Acquire Trading Securities Held-for-investment			300,000
MedVend Holdings LLC [Member] | Amount Disbursed as an Additional Investment [Member]
NOTE 4 - INVESTMENTS (Details) [Line Items]
Payments to Acquire Trading Securities Held-for-investment			300,000
Affiliated Entity [Member]
NOTE 4 - INVESTMENTS (Details) [Line Items]
Treasury Stock, Shares (in Shares)					60,000
Affiliated Entity [Member] | Bio-Tech Medical Software [Member]
NOTE 4 - INVESTMENTS (Details) [Line Items]
Legal Fees				4,800
Stock Repurchased During Period, Shares (in Shares)				30,000
Stock Repurchased During Period, Value				604,800
Affiliated Entity [Member] | MedVend Holdings LLC [Member]
NOTE 4 - INVESTMENTS (Details) [Line Items]
Legal Fees				4,800
Stock Repurchased During Period, Shares (in Shares)				30,000
Stock Repurchased During Period, Value				$604,800

NOTE_5_INVENTORIES_Schedule_of

NOTE 5 - INVENTORIES - Schedule of Inventory, Current (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Inventory [Line Items]
Work in process and related capitalized costs	$0	$242,488
Inventory	522,198	632,986
Deposits on Dispensing Machines [Member]
Inventory [Line Items]
Inventory	336,583	138,423
Vaporizers and Accessories [Member]
Inventory [Line Items]
Inventory	164,030	193,575
Dispensing Machines [Member]
Inventory [Line Items]
Inventory	$21,585	$58,500

NOTE_5_INVENTORIES_Detail

NOTE 5 - INVENTORIES (Detail) (USD $)	3 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]
Inventory Write-down	$329,154

NOTE_6_PROPERTY_AND_EQUIPMENT_

NOTE 6 - PROPERTY AND EQUIPMENT - Schedule of Property, Plant and Equipment (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$194,763	$161,781
Less accumulated depreciation	-42,779	-21,123
Property and equipment, net	151,984	140,658
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	22,934	17,192
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	74,404	73,567
Website Development [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	46,922	46,922
Product Development [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$50,503	$24,100

NOTE_7_ASSETS_HELD_FOR_RESALE_

NOTE 7 - ASSETS HELD FOR RESALE (Detail) (Land [Member], USD $)	0 Months Ended	3 Months Ended
	Jul. 28, 2014	Sep. 30, 2014	Jul. 28, 2014	Mar. 22, 2013
Land [Member]
NOTE 7 - ASSETS HELD FOR RESALE (Details) [Line Items]
Proceeds from Sale of Property, Plant, and Equipment		$399,594
Debt Instrument, Face Amount	249,000	249,000	249,000
Debt Instrument, Maturity Date	30-Jan-15	30-Jan-15
Debt Instrument, Interest Rate, Stated Percentage		12.00%		12.00%
Debt Instrument, Date of First Required Payment	1-Aug-14	28-Jul-14
Debt Instrument, Periodic Payment, Interest		$2,490
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum	18.00%	18.00%

NOTE_7_ASSETS_HELD_FOR_RESALE_1

NOTE 7 - ASSETS HELD FOR RESALE - Schedule of Assets Held for Resale (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Long Lived Assets Held-for-sale [Line Items]
Assets held for resale	$399,594	$0
Building [Member]
Long Lived Assets Held-for-sale [Line Items]
Assets held for resale	$399,594	$0

NOTE_8_INTANGIBLE_ASSETS_Detai

NOTE 8 - INTANGIBLE ASSETS (Detail) (Vaporfection International Inc. [Member])	Mar. 22, 2013
Vaporfection International Inc. [Member]
NOTE 8 - INTANGIBLE ASSETS (Details) [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%

NOTE_8_INTANGIBLE_ASSETS_Sched

NOTE 8 - INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$871,363	$715,179
Less accumulated amortization	-70,459	-32,750
Intangible assets, net	800,904	682,429
Distribution Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	314,000	314,000
Patented Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	403,363	332,179
Internet Domain Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	131,000	46,000
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$23,000	$23,000

NOTE_8_INTANGIBLE_ASSETS_Sched1

NOTE 8 - INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets, Estimated Useful Life (Detail)	9 Months Ended
	Sep. 30, 2014
Distribution Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful lives	10 years
Internet Domain Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful lives	10 years
IP and Related Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful lives	10 years
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful lives	3 years

NOTE_9_ACCOUNTS_AND_NOTES_RECE

NOTE 9 - ACCOUNTS AND NOTES RECEIVABLE (RESTATED) (Detail) (USD $)	1 Months Ended	3 Months Ended
	Dec. 31, 2013	Sep. 30, 2014
Receivables [Abstract]
Financing Receivable, Net		$75,000
Note Receivable, Maturity Date	10-Dec-18	31-Dec-14
Note Receivable, Stated Interest Rate, Percentage	5.00%	7.50%
Note Receivable, Face Amount	1,000,000
Notes, Loans and Financing Receivable, Net, Noncurrent	0	155,000
Notes, Loans and Financing Receivable, Net, Current	$115,000	$75,000

NOTE_10_MARKETABLE_SECURITIES_

NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS - Marketable Securities (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 30, 2013
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) [Line Items]
Shares received as a payment from client	$176,400	$184,800	$184,800
Marketable Securities, Current	208,025	184,800	184,800
MJ Holdings [Member]
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) [Line Items]
Marketable Securities, Current	$31,625		$0

NOTE_10_MARKETABLE_SECURITIES_1

NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Detail) (USD $)	9 Months Ended	0 Months Ended
	Sep. 30, 2014	19-May-14	Dec. 31, 2013	Dec. 30, 2013
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Marketable Securities [Line Items]
Marketable Securities, Current	$208,025		$184,800	$184,800
Marketable Securities, Number of Shares Held as Deposit (in Shares)	7,000,000
Marketable Securities, Value of Shares Held as Customer Deposit	300,000
Fair Value Inputs, Discount Rate	12.00%
Marketable Securities, Restricted, Current	176,400		184,800	184,800
Class of Warrant or Right, Outstanding (in Shares)	295,854
MJ Holdings [Member]
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Marketable Securities [Line Items]
Marketable Securities, Current	31,625			0
Investment, Percentage of Profits Realized from Investment		50.00%
Investment, Term of Investment		6 months
Class of Warrant or Right, Outstanding (in Shares)		33,333
Class of Warrant or Rights, Granted (in Shares)	5
Class of Warrant or Rights, Exercised (in Shares)	10,825
Class of Warrant or Rights, Fair Value Granted	$21,758

NOTE_10_MARKETABLE_SECURITIES_2

NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS - Schedule of Marketable Securities (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014	Jun. 19, 2014	19-May-14
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	$31,625	$190,132	$0
Fair Value at Conversion	-158,507
Warrant #3 [Member]
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	834	53,867
Fair Value at Conversion	-53,033
Warrant #4 [Member]
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	1,267	30,600
Fair Value at Conversion	-29,333
Warrant # 5 [Member]
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	7,133	7,133
Fair Value at Conversion	0
Warrant [Member] | Warrant #1 [Member]
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	0	95,866	-94,719
Fair Value at Conversion	-1,147
Warrant [Member] | Warrant #2 [Member]
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	633	2,666
Fair Value at Conversion	-2,033
Convertible Debt Securities [Member]
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Schedule of Marketable Securities [Line Items]
Warrant Fair Value	21,758	0	94,719
Fair Value at Conversion	($72,961)

NOTE_10_MARKETABLE_SECURITIES_3

NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS - Schedule of Marketable Securities (Parenthetical) (Detail) (Convertible Debt Securities [Member])	9 Months Ended
	Sep. 30, 2014
Convertible Debt Securities [Member]
NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS (Details) - Schedule of Marketable Securities [Line Items]
Conversion of the Warrant, shares	10,825

NOTE_10_MARKETABLE_SECURITIES_4

NOTE 10 - MARKETABLE SECURITIES AND CUSTOMER DEPOSITS - Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques (Detail) (USD $)	0 Months Ended	9 Months Ended
	19-May-14	Sep. 30, 2014	19-May-14
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Number of warrants/shares (in Shares)		295,854
Warrant #1 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price, $	$8.69		$8.69
Exercise price, $	$6.42		$6.42
Time to maturity, Years	6 months
Annual risk-free rate, %	0.05%
Annualized volatility, %	70.00%
Black-Scholes Value per warrant, $	$2.88		$2.88
Number of warrants/shares (in Shares)	33,333		33,333
Total value of warrants/shares, $ (in Dollars)	$95,866		$95,866
Warrant #2 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price, $	$4	$2.01	$4
Exercise price, $	$8.45	$8.45	$8.45
Time to maturity, Years	6 months	1 year
Annual risk-free rate, %	0.05%	0.13%
Annualized volatility, %	70.00%	70.00%
Black-Scholes Value per warrant, $	$0.08	$0.02	$0.08
Number of warrants/shares (in Shares)	33,333	33,333	33,333
Total value of warrants/shares, $ (in Dollars)	2,666	633	2,666
Warrant #3 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price, $	$8	$2.01	$8
Exercise price, $	$7.87	$7.87	$7.87
Time to maturity, Years	6 months	1 year
Annual risk-free rate, %	0.05%	0.13%
Annualized volatility, %	70.00%	70.00%
Black-Scholes Value per warrant, $	$1.62	$0.03	$1.62
Number of warrants/shares (in Shares)	33,333	33,333	33,333
Total value of warrants/shares, $ (in Dollars)	53,867	834	53,867
Warrant #4 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price, $	$6.15	$2.01	$6.15
Exercise price, $	$6.95	$6.95	$6.95
Time to maturity, Years	6 months	1 year
Annual risk-free rate, %	0.05%	0.13%
Annualized volatility, %	70.00%	70.00%
Black-Scholes Value per warrant, $	$0.92	$0.04	$0.92
Number of warrants/shares (in Shares)	33,333	33,333	33,333
Total value of warrants/shares, $ (in Dollars)	30,600	1,267	30,600
Warrant # 5 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price, $	$2.01	$2.01	$2.01
Exercise price, $	$3.53	$3.53	$3.53
Time to maturity, Years	1 year	1 year
Annual risk-free rate, %	0.04%	0.13%
Annualized volatility, %	70.00%	70.00%
Black-Scholes Value per warrant, $	$0.21	$0.21	$0.21
Number of warrants/shares (in Shares)	33,333	33,333	33,333
Total value of warrants/shares, $ (in Dollars)	$7,133	$7,133	$7,133

NOTE_11_CUSTOMER_DEPOSITS_Cust

NOTE 11 - CUSTOMER DEPOSITS - Customer Advances and Deposits, Current (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Customer Advances and Deposits, Current [Abstract]
Advance payments from customers	$1,509,770	$710,225
Advance payments for vaporizers	75,038	75,636
Total customer deposits	$1,584,808	$785,861

NOTE_12_SHORTTERM_DEBT_Schedul

NOTE 12 - SHORT-TERM DEBT - Schedule of Short-term Debt (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Schedule of Short-term Debt [Abstract]
Notes payable to unrelated third party	$299,605	$75,000
Notes payable to related party	491,674	111,794
Total short-term debt	$791,279	$186,794

NOTE_12_SHORTTERM_DEBT_Detail

NOTE 12 - SHORT-TERM DEBT (Detail) (USD $)	9 Months Ended		0 Months Ended	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Jul. 28, 2014	Sep. 30, 2014	Mar. 22, 2013
NOTE 12 - SHORT-TERM DEBT (Details) [Line Items]
Repayments of Notes Payable	$75,000	$0
Land [Member]
NOTE 12 - SHORT-TERM DEBT (Details) [Line Items]
Debt Instrument, Face Amount	249,000		249,000	249,000
Debt Instrument, Interest Rate, Stated Percentage	12.00%			12.00%	12.00%
Debt Instrument, Date of First Required Payment			1-Aug-14	28-Jul-14
Debt Instrument, Maturity Date			30-Jan-15	30-Jan-15
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum			18.00%	18.00%
Debt Instrument, Periodic Payment, Interest				2,490
Notes Payable, Other Payables [Member]
NOTE 12 - SHORT-TERM DEBT (Details) [Line Items]
Debt Instrument, Face Amount	22,160			22,160
Debt Instrument, Interest Rate, Stated Percentage	5.99%			5.99%
Debt Instrument, Date of First Required Payment	5-Sep-14
Debt Instrument, Maturity Date	5-May-15
Debt Instrument, Periodic Payment, Interest	2,524
Notes Payable [Member]
NOTE 12 - SHORT-TERM DEBT (Details) [Line Items]
Debt Instrument, Face Amount	50,605			50,605
D&O Insurance Financing [Member]
NOTE 12 - SHORT-TERM DEBT (Details) [Line Items]
Debt Instrument, Face Amount	137,160			137,160
Debt Instrument, Interest Rate, Stated Percentage	4.25%			4.25%
Debt Instrument, Date of First Required Payment	5-Mar-14
Debt Instrument, Maturity Date	5-Nov-14
Debt Instrument, Frequency of Periodic Payment	Monthly
Debt Instrument, Periodic Payment	$15,511
Debt Instrument, Term	9 months

NOTE_13_CONVERTIBLE_NOTES_PAYA

NOTE 13 - CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY (Detail) (USD $)	9 Months Ended		0 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 19, 2014	Jul. 21, 2014	Aug. 26, 2014	Sep. 26, 2014
NOTE 13 - CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY (Details) [Line Items]
Proceeds from Convertible Debt	$3,500,000	$0
Convertible Debt [Member]
NOTE 13 - CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY (Details) [Line Items]
Debt Instrument, Maturity Date			19-Sep-15	21-Jul-15
Debt Instrument, Description	In connection with each of the purchase agreements, the Company entered into a registration rights agreement with the respective investors, pursuant to which the Company agreed to file a registration statement for the resale of the shares of common stock issuable upon conversion of, or payable as principal and interest on, the respective debentures, within 45 days of the initial closing date under each agreement, and to have such registration statements declared effective within 120 days of the initial closing dates of each purchase agreement.		The second closing, of $1,500,000, is to occur within 2 days of the effective date of the registration statement filed by the Company for the resale of the shares of common stock issuable upon conversion of the September 2014 Purchase Agreement Debentures.	The fourth and fifth, each in the amount of $500,000, are to occur within 2 and 5 business days, respectively, of the effective date of the registration statement filed by the Company for the resale of the shares of common stock issuable upon conversion of the July 2014 Purchase Agreement Debentures.
Debt Instrument, Face Amount			2,500,000	3,500,000
Proceeds from Convertible Debt			1,000,000
Debt Instrument, Interest Rate, Stated Percentage			5.00%	10.00%
Debt Instrument, Payment Terms			Repayment, including accrued principal and accrued interest, due in nine monthly installments, commencing the fourth month after issuance.	Repayment, including accrued principal and accrued interest, beginning on the eleventh day of the fourth month after issuance and will continue on the eleventh day of each following 8 successive months thereafter.
Debt Instrument, Convertible, Conversion Price	$11.75
Debt Instrument, Convertible, Terms of Conversion Feature	The Company may make payments on the debt in cash, prompting a 30% premium or, subject to certain conditions, in shares of common stock valued at 70% of the lowest volume weighted average price of the common stock for the 20 prior trading days. However, in the event the registration statement filed by the Company in connection with the respective purchase agreements is not effective within 120 days of the initial closing date under the July 2014 Purchase Agreement and 120 days of the initial closing date under the September 2014 Purchase Agreement, the July 2014 Purchase Agreement Debenturesb and the September 2014 Purchase Agreement Debenturesb, respectively, conversion rate will be, during the period commencing 120 days after the initial closing date until the registration statement is effective, equal to 63% of the lowest volume weighted average price of the common stock for the 20 prior trading days. If the aforementioned registration statement is not effective within 160 days of the initial closing date, each of the debenturesb conversion rate will be, during the period commencing 160 days after the initial closing date until the registration statement is effective, equal to 60% of the lowest volume weighted average price of the common stock for the 20 prior trading days.
Debt Issuance Cost				227,500
Derivative Liability				1,776,000
Debt Instrument, Tranche One [Member] | Convertible Debt [Member]
NOTE 13 - CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY (Details) [Line Items]
Proceeds from Convertible Debt				1,000,000
Debt Instrument, Tranche Two [Member] | Convertible Debt [Member]
NOTE 13 - CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY (Details) [Line Items]
Proceeds from Convertible Debt					1,000,000
Debt Instrument, Tranche Three [Member] | Convertible Debt [Member]
NOTE 13 - CONVERTIBLE NOTES PAYABLE AND DERIVATIVE LIABILITY (Details) [Line Items]
Proceeds from Convertible Debt						$500,000

NOTE_14_PREPAID_EXPENSES_AND_O

NOTE 14 - PREPAID EXPENSES AND OTHER CURRENT ASSETS - Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Prepaid expenses
Deferred loan cost	$196,250	$0
Rent	5,262	3,962
Directors & officers insurance	77,645	0
Professional fees	30,000	52,739
Other vendors	68,750	32,540
Other current assets
Earnest money deposits, net	634,288	0
Prepaid expenses and other current assets	$1,012,195	$89,241

NOTE_15_RESTRICTED_STOCK_AND_R

NOTE 15 - RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") (Detail) (USD $)	0 Months Ended			9 Months Ended
	Sep. 08, 2014	Aug. 21, 2014	Jul. 23, 2014	Sep. 30, 2014
NOTE 15 - RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") (Details) [Line Items]
Employment Agreement, Term			2 years
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award			Under the Equity Incentive Plan adopted by the Company, in the amount of the greater (by value) of 50,000 shares of common stock or $500,000 of common stock based on the volume weighted average price for the 30 day period prior to the date of the grant.
Stock Issued During Period, Value, Restricted Stock Award, Gross			$711,500
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period			1 year
Number of Board Members	2	2
Restricted Stock [Member]
NOTE 15 - RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") (Details) [Line Items]
Stock Issued During Period, Value, Restricted Stock Award, Gross		3,607,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		346,875		346,875
Restricted Stock Units (RSUs) [Member]
NOTE 15 - RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") (Details) [Line Items]
Stock Issued During Period, Value, Restricted Stock Award, Gross		1,267,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		121,875		171,875
Number of shares underlying restricted stock		121,875

NOTE_15_RESTRICTED_STOCK_AND_R1

NOTE 15 - RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") - Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Detail) (USD $)	0 Months Ended	9 Months Ended
	Aug. 21, 2014	Sep. 30, 2014
Restricted Stock [Member]
NOTE 15 - RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") (Details) - Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Line Items]
Restricted stock non-vested at January 1, 2014		0
Restricted stock granted	346,875	346,875
Restricted stock vested		-178,125
Restricted stock forfeited		0
Restricted stock non-vested at September 30, 2014		168,750
Restricted stock non-vested at January 1, 2014		$0
Restricted stock granted		$10.40
Restricted stock vested		$10.40
Restricted stock forfeited		$0
Restricted stock non-vested at September 30, 2014		$10.40
Restricted Stock Units (RSUs) [Member]
NOTE 15 - RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") (Details) - Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Line Items]
Restricted stock non-vested at January 1, 2014		0
Restricted stock granted	121,875	171,875
Restricted stock vested		-115,625
Restricted stock forfeited		0
Restricted stock non-vested at September 30, 2014		56,250
Restricted stock non-vested at January 1, 2014		$0
Restricted stock granted		$10.40
Restricted stock vested		$10.40
Restricted stock forfeited		$0
Restricted stock non-vested at September 30, 2014		$10.40

NOTE_15_RESTRICTED_STOCK_AND_R2

NOTE 15 - RESTRICTED STOCK AND RESTRICTED STOCK UNITS ("RSUs") - Allocation of Recognized Period Costs (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation	$1,031,640	$0	$1,031,640	$0
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation	663,262		663,262
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation	$368,378		$368,378

NOTE_16_RELATED_PARTY_TRANSACT

NOTE 16 - RELATED PARTY TRANSACTIONS (Detail) (USD $)

0 Months Ended

12 Months Ended

9 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

Sep. 08, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Jun. 30, 2014

Jul. 21, 2014

Sep. 30, 2014

Oct. 09, 2014

Nov. 11, 2014

Mar. 31, 2014

Nov. 01, 2014

Oct. 28, 2013

Sep. 30, 2013

Sep. 20, 2013

Mar. 28, 2014

Mar. 25, 2014

NotesPayable

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Deposits and other assets

$98,726

$72,726

$72,726

$72,726

Stock Issued During Period, Shares, Share-based Compensation, Gross (in Shares)

346,875

Affiliated Entity [Member] | Vincent Chase Inc. [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

100.00%

100.00%

100.00%

100.00%

Number of Promissory Notes

2

Debt Instrument, Face Amount

100,000

100,000

100,000

100,000

150,000

Due to Related Parties, Current

111,794

491,674

491,674

491,674

Debt Instrument, Interest Rate, Stated Percentage

0.00%

0.00%

0.00%

Affiliated Entity [Member] | Vincent Chase Inc. [Member] | Annual Advisory And Consulting Service Fee [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Related Party Transaction, Amounts of Transaction

150,000

Affiliated Entity [Member] | Vincent Chase Inc. [Member] | Monthly Advisory and Consulting Service Fee [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Related Party Transaction, Amounts of Transaction

25,000

12,500

Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Equity Method Investment, Ownership Percentage

100.00%

100.00%

100.00%

Number of Promissory Notes

4

Due to Related Parties, Current

391,674

391,674

391,674

Repayments of Related Party Debt

75,000

Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member] | Note Payable #1 [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Instrument, Face Amount

250,000

250,000

250,000

Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member] | Note Payable #2 [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Instrument, Face Amount

100,000

100,000

100,000

Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member] | Note Payable 3 [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Instrument, Face Amount

500,000

500,000

500,000

Affiliated Entity [Member] | PVM International Inc. (PVMI) [Member] | Note Payable #4 [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Debt Instrument, Face Amount

375,000

375,000

375,000

Affiliated Entity [Member] | Dr. Bruce Consulting [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Related Party Transaction, Amounts of Transaction

18,750

500,000

Equity Method Investment, Ownership Percentage

100.00%

100.00%

100.00%

Affiliated Entity [Member] | Subsequent Event [Member] | PVM International Inc. (PVMI) [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Repayments of Related Party Debt

3,197

Affiliated Entity [Member] | Subsequent Event [Member] | Dr. Bruce Consulting [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Related Party Transaction, Amounts of Transaction

12,500

Equity Method Investment, Ownership Percentage

100.00%

Related Party And Shareholder [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Related Party Transaction, Amounts of Transaction

150,000

Deposits and other assets

500,000

400,000

Chief Executive Officer [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Gross (in Shares)

20,000

Chief Executive Officer [Member] | Restricted Stock Units (RSUs) [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted (in Shares)

50,000

Chief Executive Officer [Member] | Subsequent Event [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Stock Issued During Period, Value, Share-based Compensation, Forfeited

$20,000

Chief Executive Officer [Member] | Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted (in Shares)

70,000

Chief Executive Officer [Member] | Subsequent Event [Member] | Additional Award [Member] | Restricted Stock Units (RSUs) [Member]

NOTE 16 - RELATED PARTY TRANSACTIONS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted (in Shares)

20,000

NOTE_17_STOCKHOLDERS_EQUITY_De

NOTE 17 - STOCKHOLDER'S EQUITY (Detail) (USD $)

0 Months Ended

9 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

0 Months Ended

Sep. 08, 2014

Aug. 21, 2014

Feb. 03, 2014

Dec. 19, 2013

Sep. 30, 2014

Sep. 30, 2013

Mar. 31, 2014

Nov. 30, 2011

Dec. 31, 2012

Jan. 31, 2013

Jun. 05, 2014

Dec. 31, 2013

NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]

Treasury Stock, Shares

60,000

Proceeds from Issuance of Common Stock (in Dollars)

$2,442,859

$3,541,090

Dividends Payable, Nature

declared a 1:1 common stock dividend on each share of outstanding common stock

Common Stock Dividends, Shares

14,762,875

Stock Issued During Period, Shares, Share-based Compensation, Gross

346,875

Number of Board Members

2

2

Common Stock Issuance [Member]

NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]

Stock Issued During Period, Shares, New Issues

485,830

Sale of Stock, Price Per Share (in Dollars per share)

$5

Proceeds from Issuance of Common Stock (in Dollars)

2,427,859

Series A Preferred Stock [Member]

NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]

Preferred Stock, Par or Stated Value Per Share (in Dollars per share)

$0.00

$0.00

Preferred Stock, Shares Outstanding

3,000,000

3,000,000

Series A Preferred Stock [Member] | Stock Issued to Founder and Shareholder [Member]

NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]

Stock Issued During Period, Shares, New Issues

6,000,000

Preferred Stock, Par or Stated Value Per Share (in Dollars per share)

$0.00

Convertible Preferred Stock, Terms of Conversion

converted to common stock at a ratio of 1 (one) share of Series A Preferred Stock to 5 (five) shares of common stock

Series A Preferred Stock [Member] | Stock Issued To Shareholder [Member]

NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]

Stock Repurchased During Period, Shares

3,000,000

Series A Preferred Stock [Member] | Stock Issued to Founder [Member]

NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]

Stock Repurchased and Retired During Period, Shares

3,000,000

Affiliated Entity [Member]

NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]

Treasury Stock, Shares

60,000

Board Member [Member]

NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Gross

93,751

Bio-Tech Medical Software [Member] | Affiliated Entity [Member]

NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]

Stock Repurchased During Period, Shares

30,000

Legal Fees (in Dollars)

4,800

Stock Repurchased During Period, Value (in Dollars)

604,800

MedVend Holdings LLC [Member] | Affiliated Entity [Member]

NOTE 17 - STOCKHOLDER'S EQUITY (Details) [Line Items]

Stock Repurchased During Period, Shares

30,000

Legal Fees (in Dollars)

4,800

Stock Repurchased During Period, Value (in Dollars)

$604,800

NOTE_18_COMMITMENTS_AND_CONTIN

NOTE 18 - COMMITMENTS AND CONTINGENCIES (Detail) (USD $)	3 Months Ended		9 Months Ended		0 Months Ended						1 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 17, 2013	Oct. 17, 2014	Aug. 01, 2011	Jul. 01, 2014	Jul. 22, 2014	8-May-14	Jul. 31, 2014
											Agreement
NOTE 18 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense	$53,114	$48,069	$156,716	$91,983
Payments to Acquire Real Estate			399,594	0
Real Estate, Purchase Price	23,030,000		23,030,000
Vaporfection International Inc. [Member]
NOTE 18 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals					1,981
Lessee Leasing Arrangements, Operating Leases, Term of Contract					1 year
Amount committed to purchase unused components			56,000
Subsequent Event [Member]
NOTE 18 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Payments to Acquire Real Estate						50,000
Office Lease, West Hollywood, California [Member]
NOTE 18 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Lease Expiration Date							30-Jun-17
Operating Leases, Rent Expense, Minimum Rentals							14,397
Office Lease, West Hollywood, California [Member] | Subsequent Event [Member]
NOTE 18 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Lease, Rent Increase, Percent								3.00%
Operating Leases, Rent Expense								14,828
Office Facilities Lease, West Hills, California [Member]
NOTE 18 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals			1,300
Office Facilities Lease, Scottsdale, Arizona [Member]
NOTE 18 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals			1,420
Virtial Office Lease, Tokyo, New York, Seattle and Toronto [Member]
NOTE 18 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals			390
Description of Lessee Leasing Arrangements, Operating Leases			month to month basis
Land and Building [Member]
NOTE 18 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals									20,000	7,400
Lessee Leasing Arrangements, Operating Leases, Term of Contract									5 years	5 years
Security Deposit									30,000
Escrow Deposits Related to Property Sales			634,288
Payments to Acquire Real Estate			23,030,000
Real Estate, Purchase Price	399,594		399,594
Notes Issued	249,000
Potential Real Estate Purcahse Foreclosed Upon [Member] | Land and Building [Member]
NOTE 18 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Number of Real Estate Purchase Agreements											1
Proceeds from Other Deposits											10,000
Forfeiture Of Earnest Money On Potential Purchase Of Real Estate [Member] | Land and Building [Member]
NOTE 18 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Real Estate, Purchase Price											2,500,000
Number of Real Estate Purchase Agreements											2
Earnest Money Forfeited											$100,000

NOTE_18_COMMITMENTS_AND_CONTIN1

NOTE 18 - COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Rental Payments for Operating Leases (Detail) (USD $)	Sep. 30, 2014
Building [Member]
NOTE 18 - COMMITMENTS AND CONTINGENCIES (Details) - Schedule of Future Minimum Rental Payments for Operating Leases [Line Items]
2014	$44,484
2015	177,936
2016	177,936
2017	88,968
2018	0
2019	0
Total	489,324
Land and Building [Member]
NOTE 18 - COMMITMENTS AND CONTINGENCIES (Details) - Schedule of Future Minimum Rental Payments for Operating Leases [Line Items]
2014	22,200
2015	88,800
2016	88,800
2017	88,800
2018	88,800
2019	29,600
Total	$407,000

NOTE_18_COMMITMENTS_AND_CONTIN2

NOTE 18 - COMMITMENTS AND CONTINGENCIES - Schedule of Real Estate Properties (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Real Estate Properties [Line Items]
Purchase price	$23,030,000
Net escrow balance	634,288
Additional rents/fees paid to extend closing date	7,893
Property 1 [Member]
Real Estate Properties [Line Items]
Purchase price	3,500,000
Closing date	12/11/14
Net escrow balance	60,000
Date escrow opened	7/25/14
Additional rents/fees paid to extend closing date	0
Property 2 [Member]
Real Estate Properties [Line Items]
Purchase price	3,650,000
Closing date	1/5/15
Net escrow balance	35,000
Date escrow opened	7/21/14
Additional rents/fees paid to extend closing date	0
Property 3 [Member]
Real Estate Properties [Line Items]
Purchase price	2,450,000
Closing date	12/1/14
Net escrow balance	80,000
Date escrow opened	8/13/14
Additional rents/fees paid to extend closing date	0
Property 4 [Member]
Real Estate Properties [Line Items]
Purchase price	790,000
Closing date	1/1/15
Net escrow balance	24,288
Date escrow opened	8/12/14
Additional rents/fees paid to extend closing date	0
Property 5 [Member]
Real Estate Properties [Line Items]
Purchase price	480,000
Closing date	1/31/15
Net escrow balance	16,000
Date escrow opened	8/12/14
Additional rents/fees paid to extend closing date	0
Property 6 [Member]
Real Estate Properties [Line Items]
Purchase price	2,100,000
Closing date	2/10/15
Net escrow balance	90,000
Date escrow opened	8/13/14
Additional rents/fees paid to extend closing date	0
Property 7 [Member]
Real Estate Properties [Line Items]
Purchase price	595,000
Closing date	1/31/15
Net escrow balance	10,000
Date escrow opened	8/13/14
Additional rents/fees paid to extend closing date	0
Property 8 [Member]
Real Estate Properties [Line Items]
Purchase price	3,250,000
Closing date	2/10/15
Net escrow balance	90,000
Date escrow opened	8/19/14
Additional rents/fees paid to extend closing date	0
Property 9 [Member]
Real Estate Properties [Line Items]
Purchase price	2,400,000
Closing date	2/8/15
Net escrow balance	19,000
Date escrow opened	8/19/14
Additional rents/fees paid to extend closing date	0
Property 10 [Member]
Real Estate Properties [Line Items]
Purchase price	2,300,000
Closing date	1/8/15
Net escrow balance	80,000
Date escrow opened	8/19/14
Additional rents/fees paid to extend closing date	0
Property 11 [Member]
Real Estate Properties [Line Items]
Purchase price	695,000
Closing date	10/18/14
Net escrow balance	10,000
Date escrow opened	6/28/14
Additional rents/fees paid to extend closing date	0
Property 12 [Member]
Real Estate Properties [Line Items]
Purchase price	820,000
Closing date	10/18/14
Net escrow balance	45,000
Date escrow opened	6/28/14
Additional rents/fees paid to extend closing date	7,893
Property 13 [Member]
Real Estate Properties [Line Items]
Purchase price	0
Net escrow balance	75,000
Date escrow opened	7/21/14
Additional rents/fees paid to extend closing date	$0

NOTE_19_RESTATEMENT_Detail

NOTE 19 - RESTATEMENT (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Accounting Changes and Error Corrections [Abstract]
Transactions with related parties improperly recorded as revenue instead of capital contributions	$810,000

NOTE_19_RESTATEMENT_Restated_C

NOTE 19 - RESTATEMENT - Restated Consolidated Balance Sheet (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 30, 2013	Sep. 30, 2013	Dec. 31, 2012
Assets
Cash and cash equivalents	$1,350,442	$168,003		$100,301	$1,026,902
Marketable securities	208,025	184,800	184,800
Accounts receivable	32,312	339,735
Notes receivable	75,000	115,000
Inventory	522,198	632,986
Prepaid expenses and other current assets	1,012,195	89,241
Total current assets	3,200,172	1,529,765
Property and equipment	151,984	140,658
Assets held for resale	399,594	0
Investments, at cost	0	1,200,000
Intangible assets	800,904	682,429
Note receivable	155,000	0
Goodwill	1,100,037	1,090,037
Deposits and other assets	72,726	98,726
Total assets	5,880,417	4,741,615
Liabilities and stockholders' equity
Accounts payable and accrued expenses	1,321,998	448,314
Deferred revenue	1,073,932	683,621
Notes payable	299,605	75,000
Related party notes payable	491,674	111,794
Convertible notes payable	1,939,801	0
Derivative liability	1,228,108	0
Customer deposits	1,584,808	785,861
Total current liabilities	7,939,926	2,104,590
Stockholders' Equity
Preferred stock	3,000	3,000
Common stock	30,105	29,526
Additional paid-in capital	11,615,278	8,156,358
Common stock subscribed	0	-15,000
Treasury stock	-1,209,600	0
Accumulated deficit	-12,339,785	-5,536,859
Accumulated other comprehensive loss	-158,507	0
Total stockholders' equity	-2,059,509	2,637,025			-153,629
Total liabilities and stockholders' equity	5,880,417	4,741,615
As Originally Presented [Member]
Assets
Cash and cash equivalents	1,350,442
Marketable securities	208,025
Accounts receivable	337,475
Notes receivable	75,000
Inventory	2,466,897
Prepaid expenses and other current assets	1,012,195
Total current assets	5,450,034
Property and equipment	151,984
Assets held for resale	399,594
Investments, at cost	0
Intangible assets	800,904
Note receivable	155,000
Goodwill	1,100,037
Deposits and other assets	72,726
Total assets	8,130,279
Liabilities and stockholders' equity
Accounts payable and accrued expenses	1,505,998
Notes payable	299,605
Related party notes payable	491,674
Convertible notes payable	1,939,801
Derivative liability	1,228,108
Customer deposits	587,088
Total current liabilities	6,052,274
Stockholders' Equity
Preferred stock	3,000
Common stock	30,105
Additional paid-in capital	10,244,278
Common stock subscribed	0
Treasury stock	-1,209,600
Accumulated deficit	-6,989,778
Total stockholders' equity	2,078,005
Total liabilities and stockholders' equity	8,130,279
Impact of Restatement [Member]
Assets
Accounts receivable	-1,524,771
Inventory	-636,468
Total assets	-2,161,239
Liabilities and stockholders' equity
Accounts payable and accrued expenses	-150,000
Deferred revenue	683,621
Customer deposits	582,675
Total current liabilities	1,116,296
Stockholders' Equity
Additional paid-in capital	1,371,000
Accumulated deficit	-4,648,535
Total stockholders' equity	-3,277,535
Early Recognition of Revenue [Member]
Assets
Accounts receivable	1,219,607
Inventory	-1,308,231
Total assets	-88,623
Liabilities and stockholders' equity
Accounts payable and accrued expenses	-34,000
Deferred revenue	390,311
Customer deposits	415,045
Total current liabilities	771,356
Stockholders' Equity
Accumulated deficit	-859,979
Total stockholders' equity	-859,979
Scenario Reclassification [Member]
Assets
Total assets	0
Stockholders' Equity
Accumulated deficit	158,507
Accumulated other comprehensive loss	-158,507
Total stockholders' equity	$0

NOTE_19_RESTATEMENT_Restated_C1

NOTE 19 - RESTATEMENT - Restated Consolidated Statements of Operations And Comprehensive Loss (Detail) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Revenue	$173,076	$1,314,178	$534,082	$1,844,376
Revenue from related party	0	0	50,110	0
Less: allowances and refunds	0	0	-60,000	0
Net revenue	173,076	1,314,178	524,192	1,844,376
Cost of revenues	1,813,562	1,807,030	3,492,105	2,258,127
Gross margin	-1,640,486	-492,852	-2,967,913	-413,751
Operating expenses
Selling and marketing	319,204	91,136	749,212	506,393
Research and development	61,623	28,233	136,656	46,733
General and administrative	952,663	522,372	2,151,742	1,876,505
Stock based compensation	1,031,640	0	1,031,640	0
Total operating expenses	2,365,130	641,741	4,069,250	2,429,631
Loss from operations	-4,005,616	-1,134,593	-7,037,163	-2,843,382
Other expense
Interest income (expense), net	-339,231	4,311	-314,078	-1,884
Change in fair value of derivative liabilities	548,315	0	548,315	0
Total other income (expense)	209,084	4,311	234,237	-1,884
Loss before provision for income taxes	-3,796,532	-1,130,282	-6,802,926	-2,845,266
Provision for income taxes	0	-119,280	0	-29,220
Net loss	-3,796,532	-1,011,002	-6,802,926	-2,816,046	-3,791,440
Earnings per share attributable to common stockholders
Basic	($0.13)	($0.03)	($0.22)	($0.10)
Diluted	($0.13)	($0.03)	($0.22)	($0.10)
Weighted average shares outstanding
Basic	30,371,299	29,298,284	30,472,447	28,658,556
Diluted	30,371,299	29,298,284	30,472,447	28,658,556
Other Comprehensive loss
Net loss	-3,796,532	-1,011,002	-6,802,926	-2,816,046	-3,791,440
Unrealized loss from marketable securities	-158,507	0	-158,507	0
Comprehensive loss	-3,955,039	-1,011,002	-6,961,433	-2,816,046
Adjustment [Member]
Earnings per share attributable to common stockholders
Basic		$0
Diluted		$0
As Originally Presented [Member]
Revenue	107,429	1,980,720	836,427	4,801,062
Revenue from related party	0	0	1,000,000	0
Less: allowances and refunds	0	0	-1,229,710	0
Net revenue	107,429	1,980,720	606,717	4,801,062
Cost of revenues	743,397	1,641,495	2,183,874	2,442,592
Gross margin	-635,968	339,225	-1,577,157	2,358,470
Operating expenses
Selling and marketing	319,204	91,136	749,212	506,393
Research and development	61,623	28,233	136,656	46,733
General and administrative	1,363,440	522,372	2,682,519	1,876,505
Stock based compensation	1,031,640	0	1,031,640	0
Total operating expenses	2,775,907	641,741	4,600,027	2,429,631
Loss from operations	-3,411,875	-302,516	-6,177,184	-71,161
Other expense
Interest income (expense), net	-339,231	4,311	-314,078	-1,884
Change in fair value of derivative liabilities	548,315	0	548,315
Total other income (expense)	209,084	4,311	234,237	-1,884
Loss before provision for income taxes	-3,202,791	-298,205	-5,942,947	-73,045
Provision for income taxes	0	-119,280	0	-29,220
Net loss	-3,202,791	-178,925	-5,942,947	-43,825
Earnings per share attributable to common stockholders
Basic	($0.11)		($0.20)	$0
Diluted	($0.07)		($0.20)	$0
Weighted average shares outstanding
Basic	30,371,299	29,298,284	30,472,447	28,658,556
Diluted	45,371,299	44,298,284	30,472,447	44,372,842
Other Comprehensive loss
Net loss	-3,202,791	-178,925	-5,942,947	-43,825
As Originally Presented [Member] | Adjustment [Member]
Earnings per share attributable to common stockholders
Basic		$0
Diluted		$0
Early Recognition of Revenue [Member]
Revenue	65,647	-666,542	-302,345	-2,146,686
Revenue from related party			-949,890
Less: allowances and refunds			1,169,710
Net revenue	65,647		-82,525
Cost of revenues	1,070,165	165,535	1,308,231	-184,465
Gross margin	-1,004,518	-832,077	-1,390,756	-1,962,221
Operating expenses
General and administrative	-410,777		-530,777
Other expense
Net loss	-593,741	-832,077	-859,979	-1,962,221
Other Comprehensive loss
Net loss	-593,741	-832,077	-859,979	-1,962,221
Contributions to Capital [Member]
Revenue				-810,000
Gross margin				-810,000
Other expense
Net loss				-810,000
Other Comprehensive loss
Net loss				($810,000)

NOTE_20_SUBSEQUENT_EVENTS_Deta

NOTE 20 - SUBSEQUENT EVENTS (Detail) (USD $)

0 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

Sep. 08, 2014

Jul. 23, 2014

Sep. 30, 2014

Sep. 30, 2013

Jul. 21, 2014

Sep. 30, 2014

Sep. 30, 2014

Oct. 17, 2014

Oct. 13, 2014

Nov. 01, 2014

Oct. 31, 2014

Nov. 11, 2014

Oct. 30, 2014

Oct. 20, 2014

Oct. 16, 2014

Oct. 19, 2014

Subsequent Event [Line Items]

Payments to Acquire Real Estate

$399,594

$0

Stock Issued During Period, Shares, Share-based Compensation, Gross (in Shares)

346,875

Employment Agreement, Term

2 years

Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award

Under the Equity Incentive Plan adopted by the Company, in the amount of the greater (by value) of 50,000 shares of common stock or $500,000 of common stock based on the volume weighted average price for the 30 day period prior to the date of the grant.

Convertible Debt [Member]

Subsequent Event [Line Items]

Debt Instrument, Payment Terms

the delay in effectiveness for the Form S-1, the conversion rate for the common stock to be issued as repayment of the debentures issued pursuant to the July 2014 purchase agreement will be, during the period commencing 120 days after the initial closing date until to the registration statement is effective, reduced to 63% of the volume weighted average price for 20 days prior to the issuance from 70% of the volume weighted average price originally stipulated in the loan agreements.

MJ Holdings [Member]

Subsequent Event [Line Items]

Class of Warrant or Rights, Fair Value Granted

21,758

21,758

21,758

Office Facilities Lease, West Hills, California [Member]

Subsequent Event [Line Items]

Operating Leases, Rent Expense, Minimum Rentals

1,300

Office Facilities Lease, Scottsdale, Arizona [Member]

Subsequent Event [Line Items]

Operating Leases, Rent Expense, Minimum Rentals

1,420

Chief Executive Officer [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures (in Shares)

20,000

Stock Issued During Period, Shares, Share-based Compensation, Gross (in Shares)

20,000

Chief Executive Officer [Member] | Restricted Stock Units (RSUs) [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures (in Shares)

50,000

Affiliated Entity [Member]

Subsequent Event [Line Items]

Other Commitments, Description

non-refundable fee according to the agreement that the escrow would release to seller $10,000 on the first day of each month following the signing and additional $10,000 with signing on July 21, 2014.

Affiliated Entity [Member] | Dr. Bruce Consulting [Member]

Subsequent Event [Line Items]

Equity Method Investment, Ownership Percentage

100.00%

100.00%

100.00%

Related Party Transaction, Amounts of Transaction

18,750

500,000

Vice President [Member] | Restricted Stock Units (RSUs) [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures (in Shares)

19,452

Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in Shares)

100,000

Subsequent Event [Member]

Subsequent Event [Line Items]

Payments to Acquire Real Estate

50,000

Subsequent Event [Member] | MJ Holdings [Member]

Subsequent Event [Line Items]

Marketable Securities, Restricted

33,333

Class of Warrant or Rights, Fair Value Granted

13,033

Subsequent Event [Member] | Monthly Advisory and Consulting Service Fee [Member]

Subsequent Event [Line Items]

Other Commitment

25,000

10,000

Other Commitments, Description

The monthly consulting fee will be reduced to $12,500 per month if Mr. Mehdizadeh is engaged in trading any of the Company's securities at any time within the preceding 30 day period.

Subsequent Event [Member] | Office Facilities Lease, West Hills, California [Member] | Lease Termination [Member]

Subsequent Event [Line Items]

Operating Leases, Rent Expense, Minimum Rentals

1,300

Subsequent Event [Member] | Office Facilities Lease, Scottsdale, Arizona [Member] | Lease Termination [Member]

Subsequent Event [Line Items]

Operating Leases, Rent Expense, Minimum Rentals

1,420

Subsequent Event [Member] | Hourly Advisory And Consulting Service Fee [Member]

Subsequent Event [Line Items]

Other Commitment

200

Subsequent Event [Member] | Advisory And Consulting Services [Member] | Restricted Stock Units (RSUs) [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures (in Shares)

100,000

Subsequent Event [Member] | Chief Executive Officer [Member]

Subsequent Event [Line Items]

Stock Repurchased During Period, Shares (in Shares)

20,000

Subsequent Event [Member] | Chief Executive Officer [Member] | Restricted Stock Units (RSUs) [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures (in Shares)

70,000

Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in Shares)

20,000

Subsequent Event [Member] | Affiliated Entity [Member]

Subsequent Event [Line Items]

Escrow Deposit

190,400

Increase (Decrease) in Earnest Money Deposits Outstanding

-60,000

Non-Refundable Fee

40,000

Proceeds from Collection of Notes Receivable

155,000

Proceeds from Interest Received

6,423.56

Subsequent Event [Member] | Affiliated Entity [Member] | Dr. Bruce Consulting [Member]

Subsequent Event [Line Items]

Equity Method Investment, Ownership Percentage

100.00%

Related Party Transaction, Amounts of Transaction

12,500

Subsequent Event [Member] | Director [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Gross (in Shares)

346,875

Subsequent Event [Member] | Director [Member] | Two Board Members [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures (in Shares)

337,186

Subsequent Event [Member] | Chief Financial Officer [Member]

Subsequent Event [Line Items]

Other Commitments, Description

Pursuant to the Employment Agreement, the Company agreed to engage Mr. Mitchell, and Mr. Mitchell agreed to serve as the Company's Chief Financial Officer, for a two-year term, which term will automatically be extended for successive additional one-year terms, unless either party provides written notice to the other 90 days prior to the expiration of the initial term or any successive term, that the Employment Agreement will not be renewed.

Employment Agreement, Term

2 years

Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award

Mitchell will also be entitled to an award of restricted stock units, to be issued within 90 days of the effective date of the Employment Agreement, under the Company's Equity Incentive Plan, in the amount of 7,500 shares of common stock each calendar quarter Mr. Mitchell serves as Chief Financial Officer of the Company.

Employee Agreement, Description

Termination by the Company within 365 days of a Change of Control (as defined in the Employment Agreement) in the absence of Cause will conclusively be deemed a termination by the Company without Cause.

Subsequent Event [Member] | Chief Financial Officer [Member] | Annual Salary [Member]

Subsequent Event [Line Items]

Other Commitment

190,000

Subsequent Event [Member] | Chief Financial Officer [Member] | Living Expenses [Member]

Subsequent Event [Line Items]

Other Commitment

2,500

Subsequent Event [Member] | Chief Financial Officer [Member] | Annual Bonus [Member] | Maximum [Member]

Subsequent Event [Line Items]

Percentage of bonus on base salary

35.00%

Subsequent Event [Member] | Chief Financial Officer [Member] | Annual Cash Bonus [Member]

Subsequent Event [Line Items]

Percentage of bonus in cash

50.00%